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Résumé 
 
L’acétylation des résidus de glucosamine terminaux par la N-
acétyltransférase lysosomale (HGSNAT) est une étape essentielle de la 
dégradation catabolique de l’héparan sulfate. Des défauts dans cette réaction 
causent une maladie de surcharge lysosomale autosomale récessive rare : le 
désordre de Sanfilippo type C (SFC). À ce jour, 54 mutations ont été rapportées 
chez des patients SFC, incluant 13 mutations des sites d’épissage, 11 insertions et 
délétions, 8 mutations non-sens, 18 mutations faux-sens et 4 polymorphismes, 
avec différentes manifestations phénotypiques. Nous avons identifié 10 d’entre 
elles et effectué une étude exhaustive portant sur l’éventail des mutations SFC, 
leur distribution dans la population de patients, ainsi que leur impact potentiel sur 
la structure de la HGSNAT. Les erreurs d’épissage, les mutations non-sens, les 
insertions et les délétions devraient toutes entraîner un ARN non fonctionnel qui 
est rapidement dégradé par des mécanismes de contrôle qualité cellulaire. Les 4 
polymorphismes identifiés sont des changements d'acides aminés qui ne 
modifient pas l'activité enzymatique, la glycosylation ou la localisation et n'ont 
donc pas de signification au niveau clinique. Au niveau des enzymes, les 
polymorphismes sont des changements d’acides aminés qui n’affectent pas la 
fonction, mais dans un contexte d’acides nucléiques ils peuvent être considérés 
comme des mutations faux-sens. Les dix-huit mutations faux-sens qui ont été 
exprimées ont produit des protéines inactives, en raison d'erreurs dans leur 
repliement. Ceci expliquerait donc la progression sévère de la maladie chez les 
personnes porteuses de ces mutations. Les protéines mutantes mal repliées sont 
 iv
anormalement glycosylées et conservées dans le réticulum endoplasmique. La 
thérapie par amélioration de l’activité enzymatique par des chaperonnes est une 
option thérapeutique potentielle, spécifiquement conçue pour exploiter l'activité 
enzymatique résiduelle de mutants mal repliés, afin d’éliminer les substrats 
stockés. Nous avons démontré que le traitement de plusieurs lignées de 
fibroblastes de patients SFC avec le chlorhydrate de glucosamine, un inhibiteur 
spécifique de la HGSNAT, a partiellement restauré l’activité de l'enzyme 
mutante, fournissant une preuve de l’utilité future de la thérapie par des 
chaperonnes dans le traitement de la maladie de SFC. 
 
 
MOTS-CLÉS : 
lysosomes, désordres métaboliques, mucopolysaccharidose IIIC, syndrome de 
Sanfilippo type C, analyse mutationnelle, repliement de protéines, thérapie par 
amélioration de l’activité enzymatique. 
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ABSTRACT 
The acetylation of terminal glucosamine residues by lysosomal N-
acetyltransferase (HGSNAT) is an essential part of the catabolic breakdown of 
heparan sulfate. Defects in this reaction result in the rare autosomal recessive 
lysosomal storage disorder Sanfilippo syndrome type C (SFC). To date 54 
mutations in SFC patients have been reported including 13 splice-site mutations, 
11 insertions and deletions, 8 nonsense, 18 missense and 4 polymorphisms, with 
different phenotypic manifestations. We have identified 10 of them and 
conducted a comprehensive review discussing the spectrum of Sanfilippo C 
mutations, their distribution within the patient population as well as how the 
mutations could potentially affect the structure of HGSNAT. Splicing errors, 
nonsense mutations, insertions and deletions were all predicted to result in non-
functional RNA which is rapidly degraded by cellular quality control 
mechanisms. The 4 identified polymorphisms resulted in amino acid changes 
which did not affect the enzyme activity, glycosylation or targeting and were 
therefore not clinically significant. Polymorphisms, in the context of enzymes are 
amino acid changes not affecting function, but in the context of nucleic acids can 
still be considered as missense mutations. Eighteen missense mutations were 
expressed and shown be inactive due to errors in protein folding providing an 
explanation for the severe disease progression seen in individuals with these 
mutations. Misfolded mutants were abnormally glycosylated and retained in the 
endoplasmic reticulum. Enzyme enhancement/chaperone therapy is a potential 
treatment option specifically designed to exploit the residual enzyme activity of 
 vi
misfolded mutants in order to clear stored substrates. We demonstrated that 
treatment of several fibroblast lines of SFC patients with a specific inhibitor of 
HGSNAT; glucosamine-hydrochloride partially rescued mutant enzyme activity 
providing a proof of principle for the future use of chaperone therapeutics in the 
treatment of SFC. 
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syndrome C, mutational analysis, protein folding, enzyme enhancement therapy. 
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1.1.1 Lysosomes and lysosome biogenesis 
Lysosomes, discovered in 1949 by Belgian researcher Christian de Duve 
are cytoplasmic membrane-bound organelles carrying over 100 hydrolytic 
enzymes, including: proteases, nucleases, lipases, glycosidases, phosphatases, 
sulfatases and phospholipases. All lysosomal enzymes have acidic pH optimum 
in the range of 5.0 and are responsible for degradation and recycling of biological 
macromolecules including lipids, proteins, nucleic acids, sugars, as well as 
bacteria and non-functioning or impaired organelles such as mitochondria. There 
is only one presently known lysosomal enzyme that is not a hydrolase: heparan 
alpha-glucosaminide N-acetyltransferase (HGSNAT) which is deficient in 
patients with mucopolysaccharidosis IIIC (MPS IIIC or Sanfilippo syndrome C) 
and will be the focus of this thesis.   
 There are three main pathways involved in lysosomal catabolism. The 
first pathway involves macromolecules taken up by receptor-mediated 
endocytosis. The endocytosed material, including receptors, their ligands and 
associated membrane is initially delivered into early endosomes. Part of the cargo 
is selectively retrieved and sorted to the plasma membrane though “recycling” 
endosomes. The rest becomes part of the late endosome with a concomitant drop 
in pH and fusion with other late endosomes containing acid hydrolases from the 
Golgi apparatus to gradually form the mature lysosome. The second pathway 
involves the degradation of impaired organelles such as the mitochondria in a 
process called autophagy. In this process, the organelle is enclosed by membranes 
derived from the endoplasmic reticulum (ER), thus creating an autophagosome 
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which fuses with Golgi-derived vesicles carrying lysosomal enzymes and 
becomes a mature lysosome. The last pathway involves the uptake and 
degradation of large particles and microorganisms like bacteria, parasites and 
dead or dying cells by white blood cells (monocytes, macrophages and dendritic 
cells) collectively known as phagocytes forming phagosomes upon engulfment of 
the object, which then like the autophagosomes are acidified and filled with 
lysosomal enzymes.  
 The biogenesis of lysosomes is a complex process involving the 
integration of the endocytic and biosynthetic pathways of the cell. Lysosomal 
targeting of acid hydrolases and other lysosomal proteins can be direct, from the 
trans-Golgi network (TGN) to the endosomal system, or indirect involving 
transport to the plasma membrane and subsequent endocytosis [1, 2]. 
Furthermore, biogenesis requires that proteins destined for the lysosome are 
segregated from other proteins with different subcellular destinations and 
transferred to developing or mature lysosomes. 
 
1.1.2 Lysosomal Membrane  
The lysosomal membrane is a semi-permeable barrier between the 
lysosomal lumen and the cytoplasm that serves to protect the cytoplasmic 
proteins from degradation by the acidic hydrolases of the lysosome. The 
membrane is equipped with multiple transport and carrier systems responsible for 
controlling access into and out of the lumen in addition to containing structural 
proteins. One of the most important and well-studied lysosomal membrane 
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proteins is the proton pump that is responsible for maintaining the acidity of the 
lysosomal lumen. The proton v-ATPase pumps protons into the lumen reducing 
the pH to around 5. The membrane also facilitates transportation of degradation 
products from the lumen to the cytosol through transporters such as cystinosin 
(cystein transporter) and sialin (sialic acid transporter). Over 270 proteins have 
been identified in purified lysosomal membrane fractions through proteomic 
analysis (215 in the integral membrane and 55 in the membrane associated 
fractions), many with yet unknown functions [3]. 
Similar to proteins on other biological membranes, lysosomal membrane 
proteins are classified as associated with or integral to the membrane. The 2 most 
abundant lysosomal membrane integral proteins, lysosomal associated membrane 
proteins (LAMPs) 1 and 2, are important both structural and functional 
constituents of the membrane contributing to membrane stability, in addition to 
participating in chaperone mediated autophagy (CMA) [4, 5]. Both LAMPs serve 
as canonical lysosomal membrane markers due to their ubiquitous expression 
pattern.  
Proper functioning of lysosomal membrane proteins is essential to 
maintain cellular homeostasis. There are a number of disorders that can arise 
from defects in membrane proteins including but not limited to Nieman-Pick type 
C, sialic acid storage disease, cystinosis and MPS IIIC. 
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1.1.3 Biogenesis of lysosomal enzymes 
1.1.3.1 Sorting of soluble lysosomal proteins. 
 All known lysosomal proteins are synthesized in polyribosomes bound to 
rough ER (RER) membranes. Similar to secreted proteins, they contain an N-
terminal signal peptide consisting of domains rich in positively-charged and  
hydrophobic amino acids which directs the ribosome to the endoplasmic 
reticulum membrane and initiates transport of the growing polypeptide across the 
ER membrane, [6] where they are modified with N-linked oligosaccharide chains 
(glycans).   
The initial stages of glycoprotein synthesis involve a large precursor 
oligosaccharide Glc3Man9GlcNAc2, assembled with a pyrophosphate link to a 
ligand carrier, dolichol, and then transferred to the target asparagine residue of the 
precursor glycoprotein. While still in the RER, the signal peptide is cleaved and 
the processing of the asparagine-linked (N-linked) sugar takes place. Vesicular 
transport then shuttles proteins to the Golgi stacks where they undergo post-
translational modifications and are sorted for targeting to the lysosome, secretory 
granules or the plasma membrane. While traveling through the Golgi, the 
oligosaccharide chain residues of secretory and membrane glycoproteins are 
processed in a stepwise fashion to a complex type unit via the addition of N-
acetylglucosamine, galactose and sialic acid to mannose residues. 
In the Golgi, all soluble lysosomal glycoproteins acquire a 
phosphomannosyl recognition marker: mannose 6-phosphate (M6P) that mediates 
their future translocation to the endocytic compartment. This tag is recognized by 
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one of the two M6P receptors (M6PR), ubiquitously expressed in the TGN; the 
300-kDa cation-independent M6PR or the 46 kDa cation-dependent M6PR [7]. 
Both calcium dependent and independent receptors bind M6P with approximately 
the same affinity (7-8x10-6M), however the calcium-independent receptor binds 
diphosphorylated oligosaccharides with a much higher affinity (2x10-9M) than the 
calcium dependent receptor [8, 9]. 
The M6P marker is added in two steps. N-acetylglucosamine-1-
phosphotransferase transfers N-acetyltglucosamine-1-phosphate from UDP-
GlcNAc to one or more mannose residues on the lysosomal protein to give rise to 
a phosphodiester intermediate [10, 11]. Then the N-acetylglucosamine-1-
phosphodiester α-N-acetylglucosaminidase removes the N-acetylglucosamine 
residue to generate an active phosphomonoester [12-14]. The M6P-tagged 
glycoprotein is then ready to interact with its receptor to facilitate transport to the 
lysosome. 
The interaction between the receptors and the M6P moieties is pH-
dependent. The complex is formed at neutral or slightly acidic pH in the Golgi, 
whereas the low pH of the late endosome and lysosome favours dissociation of 
the M6P tagged enzyme from the receptor. As a result, the enzyme remains in the 
lysosome to carry out its function while the receptor is recycled back to either the 
Golgi complex or the plasma membrane where it can aid in internalizing 
exogenous ligands [15].   
Much of the evidence of a M6PR-independent sorting mechanism comes 
from studying B-lymphocytes from patients with I-cell disease. I-cell disease is 
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characterized by a deficiency in N-acetylglucosamine-phosphotransferase 
activity, and results in the lack of the ability to add M6P to newly synthesized 
hydrolases. Despite this, B-lymphocytes from patients with I-cell disease 
maintain near normal levels of lysosomal enzymes, suggesting alternative 
targeting motifs [16] 
One of these alternative routes involves the lysosomal sorting receptor: 
sortilin, that has been shown to be essential for the lysosomal trafficking of GM2 
activator protein (GM2AP), a cofactor of β-hexosaminidase A and prosaposin, a 
precursor of small proteins, saposins A-D that facilitate the catabolism of 
glycolipids in the lysosome. Intracellular trafficking experiments of prosaposin 
and GM2AP in cells transfected with a dominant negative truncated human 
sortilin demonstrated that both GM2AP and prosaposin use sortilin instead of the 
M6PR to reach the lysosome [17, 18]. Furthermore, siRNA-mediated knockdown 
of sortilin blocked the trafficking of prosaposin and GM2AP to the lysosome and 
resulted in their retention in the Golgi [19]. 
 
1.1.3.2 Sorting of lysosomal membrane proteins.  
Similar to soluble lysosomal proteins, lysosomal membrane proteins are 
glycoproteins rich in complex N-linked oligosaccharides. They are synthesized 
and glycosylated in the RER and their sugars are modified in the Golgi before 
transport to the lysosome. However, unlike the majority of soluble lysosomal 
proteins, lysosomal membrane proteins are sorted independently of M6PRs [20, 
21]. Interestingly, soluble lysosomal protein, acid phosphatase is trafficked to the 
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lysosome as a membrane bound precursor, and is cleaved from the membrane 
upon arrival in the lysosome where it becomes soluble [22]. The lysosomal 
targeting of membrane proteins involves either the internalization of proteins 
from the plasma membrane via clathrin-coated pits or direct transport from the 
Golgi.  
In both cases targeting to the lysosomes involves a complex mechanism 
requiring association of specific amino acid motifs in the cytoplasmic domains of 
the protein with a μ subunit of adaptor protein (AP) complexes [23, 24]. 
Targeting occurs via either tyrosine or dileucine based sorting signals. Tyrosine-
based sorting motifs conform to the NPXY or YXXØ (where Ø represents a 
bulky hydrophobic residue) consensus motifs. Dileucine-based signals consist of 
[DE]XXXL[LI] or DXXLL consensus motifs. YXXØ and [DE]XXXL[LI] 
signals are recognized by the AP-1, AP-2, AP-3 and AP-4 complexes, essential 
components of the protein coats associated with the cytosolic face of membranes. 
DXXLL signals are recognized by the Golgi-localized, γ-ear-containing, Arf-
binding (GGA) family of adaptor proteins via their VHS domains. Signal 
recognition events are tightly controlled via phosphorylation [2].  
Specifically, lysosomal integral memebrane protein  (LIMP)2 is targeted 
to the lysosome via a dileucine-based signal within the C-terminal cytoplasmic 
tail which interacts with AP-3 [2]. Furthermore LIMP2 was found to be the M6P-
independent trafficking receptor for beta-glucocerebrosidase [25]. LAMP-1, 
LAMP-2 and acid phosphatase are trafficked via the plasma membrane where 
their YXXØ targeting signal results in rapid internalization and lysosomal sorting 
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via interaction with AP-1 and AP-2. Sortilin and both calcium dependant and 
independent-M6PRs themselves contain the DXXLL sorting signal and are 
recognized by the VHS domains of GGAs which facilitates their transport to the 
lysosomes. Recent evidence indicates that M6PRs require both AP-1 and GGA 
for proper sorting [2, 26]. 
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1.2.1 Lysosomal Storage Disorders 
 
Intracellular homeostasis requires a delicate balance between degradation 
and synthesis of cellular components be maintained for proper cellular 
functioning. Defects in lysosomal enzymes or their cofactors, membrane 
transporters, or in biogenesis of the lysosome itself disrupt this balance and cause 
build-up and sequestering of the undegraded or unprocessed substrates within the 
lumen of the lysosome. In 1965 Belgian scientist H.G. Hers introduced the 
concept of lysosomal storage to describe how the deficiency of a lysosomal 
enzyme alpha-glucosidase could cause lethal Pompe disease. The undegraded 
substrate would gradually accumulate within the lysosomes, increasing their size 
and number, leading to cellular death and malfunctioning of the affected organ 
[27].  
 The storage of undegraded substrates usually does not occur in all cells 
but rather in distinct organs and tissues where most of degradation usually occurs 
[28]. For example, the brain is rich in glycosphingolipids because of their 
presence in neuronal membranes. Defective hydrolysis of these molecules occurs 
in GM1 and GM2 gangliosidoses as well as in Krabbe, Niemann-Pick types A and 
B and Gaucher diseases. Storage of undegraded substrates, primarily within the 
neurons results in their death and causes diverse neurological symptoms. In 
contrast, muscles which utilize glycogen as a source of energy are severely 
affected and become weakened in Pompe disease because glycogen breakdown 
requires acid alpha-glucosidase, defective in this disease. 
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 While it is widely agreed that storage of undegraded substrates leads to 
cell death and organ dysfunction, the mechanism(s) underlying processes from 
enzyme deficiency to cell death are not completely understood. In addition to 
specific toxicity of particular stored compounds such as galactocerebroside stored 
in Krabbe disease, recent studies identified several mechanisms that may be 
common for different lysosomal disorders.  First, mRNA profiles from lysosomal 
storage disorder (LSD) patient fibroblasts identified decreased expression of the 
ubiquitin C-terminal hydrolase (UCH)-L1 in 8 distinct LSD. UCH-L1 is essential 
for proper functioning of the proteasomal degradation pathway and its 
downregulation correlated with an impairment of this pathway which could 
contribute to the increased cell death observed in LSD [29]. Second, Settembre et 
al. proposed a model which identifies a block of autophagy as a crucial 
component in the pathogenesis of all LSDs. As mentioned earlier autophagy is a 
catabolic process the cell utilizes to regulate its own composition, by targeting the 
vacuolated cytoplasmic substrates to the lysosomes. According to this model, 
lysosomal accumulation of undegraded substrates results in defective fusion 
between autophagosomes and lysosomes and blocks the autophagic pathway at 
this step. As a consequence of this block, toxic proteins and dysfuctional 
mitochondria accumulate, ultimately leading to apoptosis, either directly or 
through the induction of chronic inflammation and cytokine release [30].  
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1.2.2 Lysosomal Storage Diseases overview 
There are currently at least 50 genetically distinct LSDs caused by the 
absence of one or more lysosomal enzymes [31]. Individually, these disorders are 
considered rare, and each one typically affects, fewer that 10,000 people 
worldwide, although high prevalence values have been reported in some 
populations. Taken together however, these disorders affect 1 in 5000 newborn 
children [32, 33].  Inheritance for LSDs is usually autosomal recessive or X-
linked such as in case for MPS II and Fabry disease.  
Currently almost all the genes responsible for LSDs have been cloned. 
The genetic information gained is being used primarily for establishing disease 
prognoses based on genotype-phenotype correlation and in genetic counselling 
for the affected families. In general, LSDs exhibit high allelic variation (different 
mutations on the same gene) and significant clinical heterogeneity. Clinical 
features vary between different disorders but the most common characteristics 
include hepatosplenomegaly (enlargement of spleen and liver), skeletal-muscular 
abnormalities, and neurodegeneration. 
LSDs manifest in several clinical forms with varying onsets (infantile, 
juvenile or adult) and display a correlated severity (severe, moderate, and 
attenuated). The progression and severity of the disease can be correlated with the 
residual enzyme activity, which is itself dependent on the underlying molecular 
defect(s). Often, very low amounts of residual enzyme activity can be adequate to 
carry out normal substrate clearance. Therefore, heterozygotes, whose enzyme 
activity is about 50% of normal, generally are clinically unaffected [34] and 
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patients develop symptoms when their residual enzyme activity falls below a 
critical threshold of 15 to 20%. There have even been incidences of asymptomatic 
individuals with beta-hexosaminidase A enzyme activity as low as 10% of 
normal, whereas patients with 5% activity exhibit the chronic adult onset form 
[35]. Therefore perturbations such as frame-shifts and nonsense mutations which 
leave no residual enzyme activity cause more severe, early onset illness; while 
missense mutations not affecting the enzyme active site and resulting in partially 
active enzymes correlate with the delayed onset or milder forms of the disorder. 
LSDs are grouped into several major classes based on both biochemical 
and clinical manifestation of the disease (Table 1). The largest group of LSDs, 
sphigolipidoses, is associated with deficiencies of glycosidases involved in the 
catabolism of sugar chains of glycolipids. This group includes 2 of the most 
frequent LSD; Gaucher disease and Tay-Sachs disease, which disproportionately 
affect Ashkenazi Jews, with a carrier frequency of 4.6% and 3% respectively [36, 
37]. Prior to the introduction of genetic testing, this represented a significant 
public health risk to people within this community. Tay-Sachs and the clinically 
indistinguishable Sandhoff disease are caused by defects in the degradation of 
GM2-gangliosides, secondary to mutations in the HEXA and HEXB genes, 
respectively, which encode the subunits of beta-hexosaminidase A. Interestingly, 
the AB variant of Sandhoff disease is caused by a defect in the GM2 activator 
protein (previously described), a cofactor for beta-hexosaminidase A. Gaucher 
disease is an autosomal recessive disorder caused by a deficiency of
 14
Disease    Enzyme Defect  Stored Substance Soluble or membrane protein 
 
1. Sphingolipidoses 
 
A. Gangliosidoses 
GM1-gangliosidosis   β-galactosidase  GM1 gangliosides  soluble 
Tay-Sachs    β-hexosaminidase A  GM2 gangliosides  soluble 
Sandhoff    β-hexosaminidase A&B GM2 gangliosides  soluble 
AB variant    GM2 ganglioside activator GM2 gangliosides  soluble 
 
Visceral storage disorders 
Fabry     α-galactosidase A  globotriasylceramide  soluble 
Gaucher    glucocerebrosidase  glucocerebroside  soluble 
Niemann-Pick, SMPD1-associated acid sphingomyelinase sphingomyelin  soluble 
Niemann-Pick C   NPC1 & NPC2  cholesterol/glycolipids membrane  
 
Leukodystrophies 
Krabbe    galactosylceramidase  galactocerebroside  soluble 
Metachromatic leucodsytrophy arylsulfatase A  sulfatides   soluble 
 
2. Glycoprotein Storage Disorders 
Galactosialidosis   cathepsin A   sialyloligosaccharides  soluble 
Fucosidosis    α-fucosidase   fucose    soluble 
α/β-Mannosidosis   α/β-mannosidase  mannose/oligosaccharides soluble 
Schindler     α-N-acetygalactosaminidase oligosaccharides  soluble 
 
3. Mucopolysaccharidoses 
I-Hurler    α-L-iduronidase  heparan/dermatan-sulfate soluble 
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Disease    Enzyme Defect  Stored Substance Soluble or membrane protein 
II-Hunter    iduronate-sulfatase  heparan/dermatan-sulfate soluble 
 
IIIA-Sanfilippo A   heparan N-sulfamidase heparan sulfate  soluble 
 
IIIB-Sanfilippo B   α-N-acetylglucosaminidase heparan sulfate  soluble 
 
IIIC-Sanfilippo C   heparan-α-glucosaminide heparan sulfate  membrane 
     N-acetyltransferase 
 
IIID-Sanfilippo D   N-acetylglucosamine  heparan sulfate  soluble 
     6-sulfatase    
 
IVA-Morquio A   galactose-6-sulfate sulfatase keratan/chondroitin 6-sulfate soluble 
IVA-Morquio B   β-galactosidase  keratin sulfate   soluble 
 
VI-Maroteaux-Lamy   N-acetylgalactosamine- dermatan sulfate  soluble 
     4-sulfatase    
 
VII-Sly    β-glucuronidase  heparan/dermatan/  soluble 
         Chondroitin 6-sulfate 
 
IX-Natowicz    hyaluronidase   hyaluronic acid  soluble 
 
4. Mucolipidoses (ML) 
 
MLI-Sialidosis   α-neuraminidase 1  sialyloligosaccharides  soluble 
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Disease    Enzyme Defect  Stored Substance Soluble or membrane protein 
MLII-I-cell disease   N-acetyl glucosamine-      
     1-phosphotransferase  carbohydrates/lipids  soluble 
 
MLIII-Pseudo-Hurler   N-acetyl glucosamine- carbohydrates/lipids  soluble 
polydystrophy    1-phosphotransferase 
 
 
MLIV     mucolipin I   lipids    membrane 
 
5. Other disorders 
 
Pompe     α-glycosidase   glycogen   soluble 
Wolman disease   acid lipase   cholesterol esters  soluble  
Batten disease    battenin   lipofuscines   membrane 
Cystinosis    cystinosin   cystine    membrane 
Salla disease    sialin    sialic acid   membrane 
Danon disease    LAMP2   N/A    membrane 
Cobalamin F-type disease  LMBD1   cobalamin   membrane 
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beta-glucocerebrosidase, resulting in the lysosomal accumulation of 
glycosylceramide.  
More than 30% of all lysosomal diseases are MPSs, disorders which 
affect the enzymes needed for the stepwise degradation of glycosaminoglycans 
(GAG, mucopolysaccharides). These are repeating carbohydrates generally found 
attached to proteins (proteoglycans) and include: heparan sulfate, dermatan 
sulfate, chondroitin 6-sulfate and hyaluronic acid. Because proteoglycans are 
primarily structural molecules produced by almost all cell types and are found 
mainly on the surface of cells and in the extracellular matrix, most MPSs present 
with hepatosplenomegaly, central nervous system (CNS) pathologies as well as 
skeletal and muscular abnormalities. Several of the enzymes deficient in MPS 
result in blocks of multiple GAG due to overlapping degradation pathways as 
indicated in Table 1. 
 
1.2.3 LSD therapies 
 
Forty years ago, experiments by Dr. E. Neufeld revealed that the 
metabolic defect in cultured fibroblasts from mucopolysaccharidosis patients can 
be compensated for by addition of enzymes which are secreted by cells not 
having the same defect [38]. This idea of complementation is the underlying 
principle in 2 of the 4 current therapeutic options for patients with LSD, namely 
bone marrow transplantation (BMT), and enzyme replacement therapy (ERT), the 
other 2 being enzyme enhancement/chaperone therapy (EET) and substrate 
reduction therapy (SRT). As mentioned previously in most of cases only a small 
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percentage of normal enzymatic activity is required to reduce storage to normal 
levels and to alleviate the symptoms in patients. 
 
1.2.3.1 Bone marrow transplantation 
 
Bone marrow transplantation has historically been the treatment method 
of choice for patients with MPS, specifically for Sly syndrome, Maroteaux-Lamy 
syndrome and Hurler syndrome. In this case the hematopoietic cells from the 
healthy donor become the source of enzyme for the other tissues and organs, 
including the brain through infiltration of microglia cells. In general BMT results 
in a long term survival of the patients due to sustainable enzyme production. 
BMT however, comes with large risks as the procedure has high morbidity and 
mortality rates (currently up to 10% in the best clinics) mostly due to infections, 
rejection of the transplant and graft versus host disease (GVHD). The first BMT 
used for treatment of MPS was performed by Hobbs in 1981 in a patient with 
Hurler syndrome (MPS I). The procedure led to the reversal of many of the 
clinical features [39]. After the initial success observed in Hobbs’ patient, it was 
thought that all MPSs could be treated with BMT therapy; however, despite 
several attempts further success was only realized in patients with Maroteau-
Lamy (MPS VI) and Sly (MPS VII) syndromes. 
Many of the immediate benefits realized for MPS patients treated with 
BMT occur in the organ systems and include restoration of the normal mass of 
liver and spleen [40]. CNS improvement is usually delayed and deterioration may 
only be stabilized 6-12 months post BMT due to the slow turnover of microglia 
and their replacement by donor derived cells [41]. Despite these benefits, little 
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improvement is seen in bone disease after BMT, most likely due to poor 
enzymatic penetration into the chondrocytes and a failure to correct or replace 
osteocytes [42]. 
BMT therapy has continued to be used as a therapeutic option in patients 
with Hurler syndrome (MPS I). The treatment has been shown to lead to rapid 
reduction in GAG substrate in liver, tonsils, conjunctiva, cerebrospinal fluid and 
urine. This has resulted in reduced obstruction in the airway, reduction of 
hepatosplenogmagaly and corneal clouding, as well as elimination of heart 
failure, and stabilization of myocardial muscle function [40]. As mentioned 
above, some features of the disease are not alleviated such as the skeletal 
deformities, and developmental disorders, especially in the first year post BMT. 
Patients with Maroteaux-Lamy syndrome (MPS VI) have shown 
significant improvements including enzymatic and biochemical correction, 
resolution of hepatosplenomegaly, stabilization of cardiopulmonary function and 
improvement in visual acuity and joint mobility [40]. Treatment of Sly syndrome 
(MPS VII) with BMT has led to the amelioration of symptoms in only a few 
patients. 
In summary, BMT has been shown to provide increases in patient quality 
and length of life. BMT therapy will thus continue to be a viable treatment for 
some MPS patients. At the same time scientists are exploring interventions that 
have less risk and are less invasive. 
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1.2.3.2 Enzyme Replacement Therapy 
The findings of Dr. Neufeld allowed the hypothesis that exogenous 
delivery of the missing enzyme in vivo could lead to clearance of the stored 
substrate and alleviation of the disease symptoms. This approach was further 
advanced by discovery that mannose 6-phosphate receptors on the cell surface are 
able to bind to and deliver exogenously supplied enzyme to the lysosomes of 
cultured cells [43]. These results paved the way for ERT intervention in patients 
with LSDs. 
Currently an intravenous (IV) infusion of purified recombinant enzyme 
produced in cultured Chinese hamster ovary cells or human fibroblasts is the 
standard therapy for patients with the non-neuronopathic form of Gaucher 
disease, Fabry disease, MPS I, MPS II, and Pompe disease [44, 45]. ERT for 
patients with Gaucher type 1 has been approved by the FDA since 1991. There 
are currently over 4300 patients receiving treatment and the effectiveness of the 
treament is well confirmed [44]. Patients displayed decreases in spleen and liver 
size, increase in haemoglobin and blood platelet counts as well as some 
improvement of bone structure. It is important however that ERT must begin 
early in order to prevent progressive bone disease [46].   
 In Fabry disease the major site of pathology is the vascular endothelium 
which is readily accessed by exogenous alpha-galactosidase administered via bi-
monthly IV infusion. This treatment has been shown to stabilize deteriorating 
renal function and led to improved cardiac functioning in hundreds of patients.  
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 ERT for some other MPS are now undergoing clinical trials including that 
for MPS VI and MPS IVA. Morquio A (MPS IVA) syndrome, relatively frequent 
in Quebec, is caused by the deficiency of galactosamine-6-sulfatase and 
characterized by accumulation of both keratan sulfate and chondroitin 6-sulfate in 
the lysosomes of ligaments, connective tissue, bone and cartilage. This results in 
systemic skeletal displasia, mild hepatosplenomegaly and heart valvular disease 
in addition to other skeletal deformities. Pre-clinical data from a mouse model of 
Morquio A showed reduction of storage in affected organs and tissues, providing 
a proof of concept for an ERT option for patients this syndrome [47]. 
 Despite its many therapeutic benefits ERT is not suitable for treatment of 
LSD with CNS involvement since the recombinant enzyme are is not able to 
cross the blood brain barrier and therefore cannot alleviate the CNS pathology. 
Additionally the treatment comes with a very high cost which may limit its access 
to patients. 
 
1.2.3.3 Enzyme enhancement/chaperone therapy  
 Chaperone therapy is an emerging method for therapy with the potential 
to treat many genetic diseases which are a result of misfolded or improperly 
assembled enzymes. Many lysosomal disorders are therefore candidates for such 
treatment. As previously mentioned many of these disorders have the additional 
advantage of only requiring very minimal amounts of residual enzyme activity to 
prevent or even reduce substrate accumulation. 
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Lysosomal enzymes fold into their native conformation in the ER with the 
assistance of various molecular chaperones, such as BiP, heat shock proteins and 
calnexin/calreticulin [48, 49]. Since folding is a thermodynamically controlled 
process some mutant proteins containing altered amino acid sequences tend to 
misfold into an alternative conformation. These mutants are retained in the ER 
and degraded by the proteosome pathway [50].  
It has been previously shown that competitive inhibitors that mimic 
substrate binding in the active site can work as active-site-specific chaperones 
(ASSC) of the mutant enzymes. This is accomplished by stabilizing the proper 
position of active site residues and shifting the equilibrium toward the correctly 
folded state of the enzyme [51]. As a result, the correctly folded mutant enzyme 
passes the quality-control system of the ER and undergoes further maturation and 
normal transport to the lysosome. Once a mutant enzyme-ASSC complex reaches 
the lysosome, the ASSC is replaced by the accumulated substrate which allows 
the enzyme to function thereby leading to an increase in residual enzyme activity 
in the cell and partial clearance of the stored substrate [51].  
Previous studies identified effective ASSCs for several lysosomal 
enzymes, and showed that some of them restored the impaired lysosomal 
catabolism in cultured patient cells or had a therapeutic effect in mouse models of 
GM1-gangliosidosis, GM2-gangliosidosis, Gaucher and Fabry diseases [44]. In 
all above cases ASSCs were competitive inhibitors of the deficient enzymes, 
suggesting that this strategy can be extended for other lysosomal enzymes and 
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disorders. These experiments provide a further proof of principle that chaperone 
therapy can be a viable treatment option for patients with folding disorders. 
The utilization of pharmalogical chaperones in the treatment of LSDs is 
still in its infancy. In particular, the pharmacodynamics, bioavailability and the 
ability of the drug to cross the blood brain barrier and treat CNS pathologies will 
have to be evaluated on a case by case basis before any clinical trials can even be 
proposed.  
 
1.2.3.4 Substrate Reduction Therapy 
SRT aims to lower the availability of the defective enzyme substrate to 
prevent its storage. This can be accomplished by either blocking an earlier step in 
the catabolism of the substrate, or by rerouting the affected metabolic pathway 
via altered signalling or gene silencing [52]. If such a drug can then be designed 
to cross the blood brain barrier there is a potential to target every cell in the body 
and thus provide an opportunity to ameliorate some of the CNS pathologies 
present in many LSDs.  
 SRT based on N-butyldeoxynojirimycin, an inhibitor of ceramide 
glucosyltransferase which can block the synthesis of glycoshphingolipids has 
proven to be successful in glycosphingolipid storage disorders by reducing pools 
of GM1 and GM2 gangliosides in Sandhoffs, Tay Sachs and Gaucher patients. 
Currently it has been FDA approved for the treatment of non-neuronopathic type 
1 Gaucher patients who are unwilling or unable to receive ERT [53]. 
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Additionally, SRT clinical trials for patients with late-onset Tay Sachs, Sandhoff 
disease, and Niemann-Pick disease type C are ongoing. 
Another study utilized siRNAs targeted towards XYLT1, XYLT2, GALTI 
and GALTII genes involved in the initial steps of GAG synthesis and showed that 
their inhibition was correlated with decreased synthesis of GAGs in MPS IIIa 
fibroblasts. More work is needed on animal models however; these initial results 
are very encouraging. Behavioural improvements were also seen in MPS IIIa 
mice treated with rhodamine B, a non-specific inhibitor of GAG synthesis, 
providing hope that the neurological pathologies can be improved in patients 
[54].  
Interestingly, Sandhoff mice treated with combination therapy of SRT and 
non-steroidal anti-inflammatory drugs showed synergistic effects of the two 
treatments and had a drastic increase in life expectancy. These results confirm 
that targeting more than one aspect of the disease pathology can result in a better 
therapeutic outcome [55].    
Therapeutic interventions for patients of LSDs have come a long way 
since inception, and can provide some patients with alleviation of symptoms and 
longer healthier lives. There are however certain obstacles that will need to be 
overcome in order to provide the best possible treatment outcomes for patient. 
One of the most pressing issues that will need to be addressed is the ability of 
drugs to cross the blood brain barrier thus allowing for the targeting of CNS 
pathologies. While it may be inconceivable currently to cure these diseases, the 
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advent of these and other newer therapies can help insure that patients of LSDs 
can be treated effectively.  
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1.3.1 Mucopolysaccharidosis III type C 
 Mucopolysacharidosis III (MPS III) or Sanfilippo syndrome is 
characterized by the storage of heparan sulfate in the lysosomes of all tissues and 
organs and its excretion in urine. The four subtypes of the disease are defined by 
their respective enzyme deficiencies: MPS III type A (heparan N-sulfatase); MPS 
III type B (α-N-acetylglucosaminidase); MPS III type C (N-acetyltransferase); 
and MPS III type D (N-acetylglucosamine 6-sulfatase) (Table 1). A clinical 
diagnosis is initially made by a visual evaluation then confirmed by analysis of 
GAG content in urine. Subtype determination is done via activity assay in 
fibroblasts obtained by a skin biopsy as all subtypes are clinically 
indistinguishable. All subtypes have onset in infancy or early childhood and show 
progressive and severe neurological deterioration causing hyperactivity, sleep 
disorders and loss of speech accompanied by behavioural abnormalities, 
neuropsychiatric problems, mental retardation, hearing loss, and visceral 
manifestations, such as mild hepatosplenomegaly, mild dwarfism with joint 
stiffness and biconvex dorsolumbar vertebral bodies, mild coarse faces, and 
hypertrichosis [56]. Many patients become demented and die before adulthood 
but some survive to the fourth decade with progressive dementia and retinitis 
pigmentosa [57, 58].  
MPS IIIC was described by Kresse et al. who found that three patients 
with the phenotype of Sanfilippo syndrome had deficiency of an enzyme that 
transfers an acetyl group from cytoplasmically derived acetyl-CoA to terminal α-
glucosamine residues of heparan sulfate within the lysosomes [59]. Klein et al. 
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reported a similar deficiency in 11 patients with the Sanfilippo syndrome, 
therefore suggesting that the disease is a relatively frequent subtype [60, 61]. 
Later the birth prevalence of the MPS IIIC in Australia, Portugal and the 
Netherlands was estimated at 0.07, 0.12 and 0.21 per 100,000, respectively [33, 
62, 63]. 
 
1.3.2 Heparan sulfate catabolism. 
 
Heparan sulfate is found in proteoglycans associated with the cell 
membrane in nearly all cells, but is most abundant in connective tissues [64]. It 
consists of repeating disaccharides comprised of units of sulfated L-iduronic or 
glucuronic acid linked to N-glucosamine. Heparan sulfate is degraded within the 
lysosomes by a collection of eight enzymes: four sulfatases, three exo-
glycosydases and one N-acetyltransferase, that act to take apart the disaccharide 
pairs successively at the terminus of heparan sulfate chains, until the molecule is 
fully degraded, producing free sulfate and monosaccharides (Figure 1). The first 
enzyme, iduronate sulfatase releases sulfate from the terminal 2-sulfated iduronic 
acid of the heparan sulfate chain (Fig. 1, reaction 1). Next, α-iduronidase releases 
the L-iduronic acid (reaction 2). This is followed by heparan N-sulfatase which 
removes the sulfate linked to the amino group of glucosamine (reaction 3). The 
last step is the removal of glucosamine. However,  
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Figure 1. Catabolic pathway for degradation of heparan sulfate. (1) Iduronate 
sulfatase releases sulfate from the terminal 2-sulfated iduronic acid of the heparan 
sulfate chain; (2) α-iduronidase releases the L-iduronic acid; (3) heparan N-
sulfatase removes the sulfate linked to the amino group of glucosamine; (4) 
glucosamine is acetylated by N-acetyltransferase to generate N-
acetylglucosamine which is removed (5) by α-N-acetylgucosaminidase; (6) 
glucuronic sulfatase followed by ß-glucuronidase (7) cleave the sulfate and 
glucuronic acid; (8) N-acetylglucosamine 6-sulfatase cleaves sulfate esters from 
N-acetylglucosamine-sulfate. Genetic disorders are: MPS II (1); MPS I (2); MPS 
IIIA (3); MPS IIIC (4); MPS IIIB (5); MPS VII (7); MPS IIID (8). 
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it must be first acetylated by N-acetyltransferase to generate N-acetylglucosamine 
(reaction 4) which is then removed by α-N-acetylgucosaminidase (reaction 5). 
Glucuronic sulfatase (reaction 6) followed by ß-glucuronidase (reaction 7) cleave 
the sulfate and glucuronic acid, with subsequent glucosamine hydrolysis. Lastly, 
N-acetylglucosamine 6-sulfatase cleaves sulfated esters from N-
acetylglucosamine-sulfate (reaction 8) reviewed by [65].  
 
1.3.3 Evidence for occurrence of a transmembrane acetylation reaction. 
 
The most intriguing of the enzymes of heparan sulfate catabolism is N-
acetyltransferase. The enzyme is critical for generating the acetylated version of 
glucosamine since there is no enzyme that can act on the unacetylated molecule. 
The mechanism by which it is achieved has been the topic of considerable 
investigation, since the acetyl donor, acetyl-CoA, is not stable in the lysosomal 
environment [66].  
Bame and Rome were first to report that AcCoA is not transported from 
the cytoplasm into the lysosome as a free molecule [67]. Instead, they proposed 
that the N-acetyltransferase catalyses the acetylation of heparan sulfate via a 
double displacement transmembrane reaction, with covalent linkage of the acetyl 
group to the enzyme as the intermediate [68, 69]. In this scheme AcCoA binds to 
the enzyme on the cytoplasmic side of the lysosomal membrane; the acetyl group 
is covalently transferred to a histidine residue on the enzyme followed by the 
release of CoA; then the acetylated enzyme undergoes a conformational change 
resulting in a transmembrane relocation of the bound acetyl group towards the 
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lysosomal interior. Once inside the lysosome, the acetylhistidine intermediate is 
protonated. The substrate glucosamine binds to a separate site on the enzyme and 
becomes acetylated by transfer from the acetylhistidine. The product is released 
and the enzyme returns to its original conformation (Figure 2). This mechanism 
was supported by genetic evidence which showed that lysates of 5 cell lines of 
MPS IIIC patients were able to catalyze acetylation of the lysosomal membrane 
and to carry out the acetyl-CoA/CoA exchange, but could not transfer the bound 
acetyl group to glucosamine [68]. 
 
1.3.4 The identification and cloning of the gene responsible for MPS IIIC. 
  
To identify the gene responsible for MPS IIIC, a genome-wide association 
scan on MPS IIIC patients and unaffected family members was performed. This 
allowed Ausseil et al. to map the gene to an 8.3-cM interval of chromosome 8 
[70]. The group then confirmed the chromosome 8 assignment by 
complementation of patient fibroblasts with human chromosome 8 [71]. In order 
to narrow down the size of the MPS IIIC locus, all available MPS IIIC families 
and individuals were genotyped for 22 microsatellite markers in the 
pericentromeric region of chromosome 8 [72] which further reduced the size of 
the loci. 
Based on the previous studies that defined the molecular properties of the 
lysosomal N-acetyltransferase, they searched the candidate region for a gene  
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Figure 2. Proposed catalytic mechanism for HGSNAT. (1) AcCoA binds to 
the enzyme on the cytoplasmic side of the lysosomal membrane; (2) the acetyl 
group is covalently transferred to a histidine residue on the enzyme followed by 
the release of CoA (3); (4) the acetylated enzyme undergoes a conformational 
change resulting in a transmembrane relocation of the bound acetyl group 
towards the lysosomal interior and the acetylhistidine intermediate is protenated; 
(5) the substrate glucosamine binds to a separate site on the enzyme and (6) 
becomes acetylated by transfer from the acetylhistidine; the product is released 
(7) and the enzyme returns to its original conformation (8). 
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encoding a protein with multiple transmembrane domains and a molecular weight 
of approximately 100 kDa. This allowed for the exclusion of the majority of the 
genes in the region with an exception of the TMEM76 gene. Furthermore, of all 
the genes present in the candidate interval only TMEM76 showed a statistically 
significant reduction of the transcript level in the cells of two MPS IIIC patients 
in a custom oligonucleotide-based microarray assay. Both patients were later 
shown to have nonsense mutations presumably causing mRNA decay [72]. 
Northern blot analysis revealed that transcripts were ubiquitously 
expressed in various tissues. The highest expression was detected in leukocytes, 
heart, lung, placenta, and liver, whereas in the thymus, colon, and brain, the gene 
was expressed at a much lower level, which is consistent with the expression 
patterns of lysosomal proteins. The cloning of TMEM76 as the gene responsible 
for MPS IIIC was performed independently by another lab through sequencing of 
genes identified by proteomic-based analysis of lysosomal proteins in mouse 
[73].  
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1.3.5 Biochemical properties of HGSNAT.  
  
Early work on HGSNAT determined it to be an integral membrane 
protein, requiring high concentrations of detergent to achieve proper 
solubilization and that maximum enzyme activity only occurred in the presence 
of phospholipids and glycolipids [74]. In addition to acetylation of terminal 
glucosamine residues of heparan sulfate, HGSNAT was also shown to acetylate 
several heparin derived di- and trisaccharides containing α-glucosamine residues 
at their nonreducing positions, and the monosaccharide glucosamine [75-77]  
Bame and Rome determined that the active site residue was a histidine by 
treating the lysosomal membrane with various amino acid modifying agents and 
then assaying for enzyme activity [69]. As previously mentioned Bame and Rome 
proposed that HGSNAT functions via a ping-pong (double displacement) 
mechanism involving two half-reactions whereby first HGSNAT is acetylated on 
its cytoplasmic face and then the acetyl group is transferred to glucosamine [67]. 
This mechanism was supported by genetic evidence which showed that lysates of 
5 cell lines of MPS IIIC patients were able to catalyze acetylation of the 
lysosomal membrane and to carry out the acetyl-CoA/CoA exchange, but could 
not transfer the bound acetyl group to glucosamine, whereas a sixth cell line was 
devoid of both activities [68]. In contrast Meikle proposed an alternative 
mechanism whereby the transfer of the acetyl group operates by a random-order 
ternary-complex mechanism, however they were unable to demonstrate specific 
acetylation of the lysosomal membranes [78].   
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Studies by Ausseil et al. described partially purified HGSNAT as having a 
molecular mass of 240 kDa and an isoelectric focusing point (pI) of 7.4. 
Additionally they determined that the specific activity directly correlated with 
protein concentration, suggesting that HGSNAT may be part of a multiprotein 
complex that acts to sequester heparan sulfate within the lysosomes. Ion-
exchange chromatography identified two peaks having HGSNAT activity, 
suggesting that the enzyme is composed of several subunits each with its own 
activity. Radiolabelling of the active site determined that the catalytic subunit is 
represented by a 120 kDa protein, which is supported by the absence of this 
protein from cells of MPS IIIC patients [79]. 
Identification of the TMEM76 gene revealed that a 1,908-bp coding 
sequence transcribed from 18 exons codes for the HGSNAT enzyme. The enzyme 
contains two possible ATG start codons and the deduced amino acid sequence 
predicts 11 transmembrane domains and five potential N-glycosylation sites 
oriented toward the lysosomal lumen consistent with the molecular properties of 
lysosomal N-acetyltransferase [72]. The C-terminus of the enzyme exposed to the 
cytoplasm contains a highly conserved TALWVLIAYILYRKK domain which 
was predicted to carry out lysosomal targeting.  Although no evidence has been 
put forth yet to confirm this localization signal; there is strong evidence that Leu-
Leu sequence motifs involved in the interaction with the adaptor proteins may be 
responsible for the lysosomal targeting of membrane proteins as previously 
mentioned [2]. HGSNAT does not share homology with any other protein of 
 35
known function; however its sequence is highly conserved among all species 
tested [72]. 
 
1.3.6 Mutations in HGSNAT 
 Initially, Hrebicek et al. identified 4 nonsense mutations, 3 frameshift 
mutations due to deletions or a duplication, 6 splice-site mutations, and 14 
missense mutations among 30 probands with MPS IIIC (Table 2). Whereas Fan et 
al. identified 1 splice-site mutation and 1 duplication. 
 Several studies have since been published examining the mutation 
spectrum in Dutch, Italian and Portuguese patient populations. Fedele et al. 
described nine alleles in patients of Italian origin including 3 splice-site 
mutations, 3 frameshift deletions resulting in premature stop codons, 1 nonsense 
mutation, and 2 missense mutations [80]. Ruijter et al. described 14 novel 
mutations: two splice site mutations, one frame shift mutation due to an insertion, 
three nonsense mutations and eight missense mutations. Interestingly, the two 
missense mutations p.R344C and p.S518F were very frequent among probands of 
Dutch origin and represented 22.0% and 29.3% respectively of the mutant alleles 
described. Additionally the authors described the clinical course of the disease, 
and identified delayed speech, motor development and behavioural problems in 
almost all the patients [81]. More recently a small study of MPS IIIC in the 
Portuguese patient population identified one splice-site mutation and one 
duplication mutation. Interestingly, the authors found the duplication c.525dupT 
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in 5 out of 6 patient alleles tested suggesting a possible founder effect [82].  All 
reported HGSNAT mutations are listed in Article 1 Table 1. 
 
 
1.3.7 HYPOTHESES and OBJECTIVES  
Our major hypothesis was that misfolding of mutant HGSNAT underlies 
the mechanism of the disease in MPS IIIC patients having missense mutations. 
Misfolding of the enzyme impairs its proper processing and targeting to the 
lysosome. It is retained in the ER and therefore cannot contribute any residual 
activity to clear stored heparan sulfate in lysosomes, causing the severe disease 
progression observed in patients. Consequently, if MPS IIIC is a folding disorder, 
then ASSCs can bind to and stabilize the active site of the misfolded protein 
thereby increasing HGSNAT activity in MPS IIIC patients’ cells and suggesting a 
possible treatment option. 
 We therefore propose to study the expression and biogenesis of 
recombinant HGSNAT containing missense mutations in cellular systems. For 
each missense mutants, we will determine its activity, localization, and 
processing (including the extent of glycosylation) versus a wild-type control. 
Additionally, we will investigate several potential ASSCs of HGSNAT that we 
will test in patient fibroblasts to determine if they can rescue the enzyme activity. 
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 38
Foreword 
MPS IIIC exhibits high clinical heterogeneity resulting in a large number of 
reported mutations. To better understand the effects these mutations have on the 
enzyme and how they may correlate with patient phenotype we compiled all the 
reported mutations in a “Mutation Update”. This update includes a 
comprehensive table of all MPS IIIC mutations, patients and the predicted 
changes or effect on the enzyme. The article also reports 10 novel mutations that 
we identified in specimens of 14 previously unreported MPS IIIC patients 
referred to us by our colleagues from around Quebec and the world.  
Additionally, we characterized 4 previously reported mutants as polymorphisms 
which presumably have no effect on the enzyme’s function and are therefore not 
clinically relevant.   
 Mutant identification was done by sequencing patient PCR products and 
analyzing the results against control alleles, confirmation was carried out in 
parental DNA when possible. 
 
Analyses of sequencing data, compiling parts of the mutation table as well as 
writing and editing the manuscript were conducted by Matthew Feldhammer. 
 
*Article published in Human Mutation Journal following peer review 
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ABSTRACT 
 
 Mucopolysaccharidosis type IIIC or Sanfilippo syndrome type C (MPS 
IIIC, MIM #252930) is a rare autosomal recessive disorder caused by the 
deficiency of the lysosomal membrane enzyme, heparan sulfate acetyl-CoA: α-
glucosaminide N-acetyltransferase (HGSNAT, EC 2.3.1.78), which catalyses 
transmembrane acetylation of the terminal glucosamine residues of heparan 
sulfate prior to their hydrolysis by α-N-acetylglucosaminidase.  Lysosomal 
storage of undegraded heparan sulfate in the cells of affected patients leads to 
neuronal death causing neurodegeneration and severely impaired development 
accompanied by mild visceral and skeletal abnormalities, including mild 
dwarfism, coarse facies, and joint stiffness.  To date, 50 HGSNAT mutations 
have been identified in MPS IIIC patients: 40 were previously published and 10 
novel mutations are reported here.  The mutations span the entire structure of the 
gene and include 13 splice-site mutations, 11 insertions and deletions, 8 
nonsense, and 18 missense mutations 
(http://chromium.liacs.nl/LOVD2/home.php?select_db=HGSNAT).  In addition 4 
polymorphisms result in amino acid changes that do not affect activity of the 
enzyme.  In this paper we discuss the spectrum of MPS IIIC mutations, their 
clinical presentation and distribution within the patient population, and speculate 
how the mutations may affect the structure and function of HGSNAT. 
Key words: HGSNAT, N-acetyltransferase, lysosome, heparan sulfate, 
mucopolysaccharidosis, mutation analysis. 
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BACKGROUND 
 
 More than 50 metabolic storage diseases are currently known, caused by 
genetic blocks in the breakdown of macromolecules in the lysosomes.  These 
diseases comprise ~14% of all inherited diseases of metabolism and, although 
individually rare, together affect one of every 7700 newborn children [Meikle et 
al., 1999].  More than 30% of all lysosomal diseases are mucopolysaccharidoses, 
disorders which affect the enzymes needed for the stepwise degradation of 
glycosaminoglycans (mucopolysaccharides), repeating carbohydrates generally 
found attached to proteoglycans.  One of them, heparan sulfate, is found in 
proteoglycans associated with the cell membrane in nearly all cells, but is most 
abundant in connective tissues [Gallagher 2006].  It consists of a repeating 
disaccharide comprised of units of sulfated L-iduronic or glucuronic acid linked 
to N-glucosamine.  Stepwise degradation of heparan sulfate occurs within the 
lysosomes by the concerted action of at least eight enzymes: four sulfatases 
(iduronate sulfatase, heparan N-sulfatase, glucuronate sulfatase, and N-
acetylglucosamine 6-sulfatase) three exo-glycosidases (α-iduronidase; ß-
glucuronidase and α-N-acetylglucosaminidase) and heparan sulfate acetyl-CoA: 
α-glucosaminide N-acetyltransferase (HGSNAT) that generates N-
acetylglucosamine which is then removed by α-N-acetylglucosaminidase.  
 The most biochemically intriguing of the enzymes of heparan sulfate 
catabolism is HGSNAT, the only known lysosomal enzyme that is not a 
hydrolase.  This enzyme is critical to generate the acetylated version of 
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glucosamine since none of the lysosomal glycosidases can act on the unacetylated 
molecule.  The mechanism by which this is achieved has been the topic of 
considerable investigation, since the acetyl donor, acetyl-CoA (AcCoA), is not 
stable in the acidic lysosomal environment [Rome et al., 1983].  More than 20 
years ago, Bame and Rome reported that AcCoA is not transported from the 
cytoplasm into the lysosome as a free molecule [Bame and Rome, 1985].  
Instead, they proposed that the N-acetyltransferase catalyses the acetylation of 
heparan sulfate via a ping-pong (double displacement) transmembrane reaction, 
with covalent linkage of the acetyl group to the enzyme as the intermediate 
[Bame and Rome, 1985, 1986a, 1986b].  In this scheme, AcCoA binds to 
HGSNAT on the cytoplasmic side of the lysosomal membrane; the acetyl group 
is covalently transferred to its active site and the acetylated enzyme undergoes a 
conformational change resulting in a transmembrane relocation of the bound 
acetyl group towards the lysosomal interior.  Once inside the lysosome, the 
substrate glucosamine binds to the enzyme and becomes acetylated. The product 
is then released and the enzyme returns to its original conformation. 
 Seven lysosomal storage diseases are caused by genetic deficiencies of the 
enzymes involved in heparan sulfate catabolism.  Three of them: MPS II (Hunter 
syndrome, iduronate sulfatase deficiency), MPS I (Hurler-Scheie syndrome, α-
iduronidase deficiency) and MPS VII (Sly syndrome, glucuronidase deficiency) 
also have blocks in dermatan sulfate degradation and, therefore, result in 
accumulation of both compounds.  Defects in the remaining enzymes, α-N-
acetylglucosaminidase, heparan N-sulfatase, N-acetyltransferase and N-
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acetylglucosamine 6-sulfatase, uniquely cause blocks in the catabolism of 
heparan sulfate.  They are classified as subtypes of a single disorder, MPS III or 
Sanfilippo syndrome [Sanfilippo, 1963].  No disorder has been found associated 
with glucuronate sulfatase deficiency.  
 Biochemically, MPS III is characterized by abnormal storage of heparan 
sulfate in the lysosomes of all tissues and organs and its excretion in urine.  The 
four subtypes of the disease are defined by the enzyme deficiency: MPS III type 
A (heparan N-sulfatase, MIM #252900), MPS III type B (α-N-
acetylglucosaminidase, MIM #252920), MPS III type C (HGSNAT, MIM 
#252930), and MPS III type D (N-acetylglucosamine 6-sulfatase, MIM 
#252940).  All subtypes have similar clinical phenotypes with onset in infancy or 
early childhood: progressive and severe neurological deterioration causing 
hyperactivity, sleep disorders, loss of speech accompanied by behavioral 
abnormalities, neuropsychiatric problems, mental retardation, hearing loss, and 
visceral manifestations, such as mild hepatomegaly, mild dysostosis multiplex , 
mild coarse facies, and hypertrichosis [Bartsocas et al., 1979; Valstar et al. 2008].  
Some patients experience severe mental retardation and die before adulthood but 
others survive to the fourth decade with progressive dementia and retinitis 
pigmentosa [Bartsocas et al., 1979].  Interestingly, in the very rare MPS IIIC 
patients with the onset of symptoms in adulthood the disease's progression was 
similar in severity and time course to the forms with onset in childhood [Berger-
Plantinga et al. 2004].  
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MPS IIIC was first described by Kresse et al. [1976] who found that three 
patients with the phenotype of Sanfilippo syndrome had a deficiency of an 
enzyme that transfers an acetyl group from cytoplasmically derived acetyl-CoA to 
terminal N-glucosamine residues of heparan sulfate within the lysosomes.  Klein 
et al. [1978, 1981] reported a similar deficiency in 11 patients with the Sanfilippo 
syndrome, therefore suggesting that the disease is a relatively frequent subtype.  
Later, the birth prevalence of MPS IIIC in Australia, Portugal and the 
Netherlands was estimated at 0.07, 0.12 and 0.21 per 100,000, respectively 
[Meikle et al., 1999; Pinto et al., 2004; Poorthuis et al., 1999]. 
  While the genes responsible for the other MPS’s have been known for a 
long time, the identification of HGSNAT has been hampered for almost three 
decades by the low tissue content and instability of this enzyme.  The gene was 
cloned only recently by two independent laboratories [Fan et al., 2006; Hrebicek 
et al., 2006].  Based on our previous studies that defined the chromosomal 
localization of the MPS IIIC allele [Ausseil et al., 2004] and molecular properties 
of HGSNAT [Hopwood et al., 1983; Pohlmann et al., 1981; Ausseil et al., 2006], 
we searched the centromeric region of human chromosome 8 for a gene encoding 
a protein with multiple transmembrane domains and a molecular weight of ~100 
kDa which allowed us to exclude the majority of the genes with an exception of 
the gene initially called TMEM76 [Hrebicek et al., 2006].  Furthermore, of all the 
genes present in the candidate interval only TMEM76 showed a statistically 
significant reduction of the transcript level in the cells of two MPS IIIC patients.  
Both patients were later shown to have nonsense mutations presumably causing 
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mRNA decay [Hrebicek et al., 2006].  Northern blot analysis identified two major 
transcripts of 4.5 and 2.1 kb ubiquitously expressed in various human tissues.  
The highest expression was detected in leukocytes, heart, lung, placenta, and 
liver, whereas in the thymus, colon, spleen and brain, the gene was expressed at a 
much lower level, which is consistent with the expression patterns of other 
lysosomal proteins.  A 1908 bp cDNA is transcribed from 18 exons of the gene.  
The deduced amino acid sequence predicts 11 transmembrane domains and five 
potential N-glycosylation sites (Fig. 1) oriented towards the lysosomal lumen.  
The first 39 amino acids are predicted to comprise the signal peptide with length 
and composition resembling those of lysosomal proteins.  According to 
predictions made by empirical computer algorithms, the C-terminus of the 
enzyme is exposed to the cytoplasm and contains conserved Tyr-X-X-Θ (where Θ 
is a hydrophobic bulk residue) and Leu-Leu sequence motifs involved in the 
interaction with the adaptor proteins responsible for the lysosomal targeting of 
membrane proteins [Bonifacino and Traub, 2003].  Significantly, Fan et al. 
[2006] who independently identified the HGSNAT gene by large-scale proteomic 
study of the lysosomal compartment have come to the same structure of the 
transmembrane domains.  
  
 MUTATIONS AND THEIR BIOLOGICAL RELEVANCE 
 
 A total of 50 mutations affecting almost all 18 exons and many introns of 
the HGSNAT gene are identified in MPS IIIC patients from 83 families (Table 1 
and Fig. 2).  Among them are 18 missense mutations affecting 8 of the 11 
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transmembrane segments of the enzyme as well as its luminal and cytosolic 
domains (Fig. 1).  
 Below we summarize all previously identified mutations and present them 
with a unified numbering system based on the sequence of GenBank entries 
NM_152419.2 and NG_009552.1 as reported in Fan et al. [2006], Ruijter at al. 
[2008] and Fedele et al. [2007].  We also report 10 novel mutations, including 
those identified in patient families from Pakistan, the USA, the UK, Germany, 
Greece, Turkey and Belarus.  These novel mutations were identified by 
sequencing the PCR products of patients genomic DNA as previously described 
[Hrebicek et al., 2006] and were absent in 210 control alleles.  In addition, 
confirmation of each mutation was made based on sequencing of parental DNA 
and/or of cDNA from patients cultured skin fibroblasts when available.  All the 
published variants have been entered in a locus specific database (LSDB) 
available online at 
http://chromium.liacs.nl/LOVD2/home.php?select_db=HGSNAT.  This database 
also contains updated information about the genotype of the MPS IIIC patients 
previously reported by Hrebicek et al. [2006] as having no mutations in the 
HGSNAT gene or having only one heterozygous mutation.  Two mutations in 
heterozygosis have now been identified for all of them.  
 
Splice site mutations 
 Ten splice site mutations potentially resulting in abnormal splicing and 
rapid degradation of mRNA have been previously identified in MPS IIIC patients 
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(Table 1); six of them (c.118+1G>A, c.234+1G>A, c.493+1G>A, c.851+5G>A, 
c.1250+1G>A and c.1726+1G>A) were reported in our publication originally 
describing the HGSNAT gene [Hrebicek et al., 2006].  Fedele et al. [2007] 
reported the mutation c.852-1G>A present in homozygosis in patients from three 
families of Italian ancestry.  The same report also described another splice 
mutation, c.1464+1G>A also found in homozygosis in a patient from the same 
region in Italy. Ruijter et al. [2007] reported one additional splice site mutation, 
c.743+1dupG in a Dutch patient and, most recently, Coutinho et al. [2008] 
reported the novel splice junction mutation c.372-2A>G which is predicted to 
result in the skipping of exon 4. 
In this study we report 3 additional splice site mutations. c.744-2A>G, 
was found in homozygosis in a patient of Pakistani origin from the UK. The 
second, c.1250+2T>C which occurs just after exon 12 was found in a patient 
from the USA in heterozygosis with the missense mutation p.A489E. The third 
novel mutation, c.1542+4dupA, was found in heterozygosis in one patient from 
the UK along with the nonsense mutation p.Y558X.  Parental DNA or patient’s 
cDNA were not available for confirmation of these mutations or of their effect on 
the mRNA.  
 
Insertions and deletions 
 Insertions and deletions can result in frame shifts and premature 
termination of translation causing rapid degradation of the resulting transcripts.  
Eight insertions and deletions affecting exons 5, 7, 11, 13, 17 and 18 of the 
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HGSNAT gene (Table 1) have been already reported.  In particular: mutations 
c.1034_1049del, c.1336_1372dup and c.1750delG in patients from Czech 
Republic, Poland and Finland, respectively, were reported in our original 
publication, whereas Fedele et al. [2007] reported mutations c.682_740del, 
c.739delA, and c.1669_1674delinsACAT present in patients of Italian origin and 
Fan [2006] found c.1345dupG in a Canadian patient.  Interestingly, the single-
base deletion, c.739delA, predicted to result in a frameshift and the appearance of 
a premature termination codon (PTC) 87 bp downstream from the deletion was 
also found in homozygous fashion in a patient from North Africa and in 
combination with p.R506X in a Belgian patient.  The mother of this Belgian 
patient who was found to be a carrier for this deletion is of Italian origin 
suggesting common ancestry for the two families.  More recently Coutinho et al. 
[2008] reported the mutation c.525dupT in Portuguese patients.  In two patients, 
the mutation was found in homozygosis and in the third, in heterozygosis with the 
splice site mutation c.372-2A>G. 
 We report here the large deletion c.1-1925_118+296del found in a 
homozygous fashion in two unrelated patients of Turkish origin.  This large 2339 
base pair deletion includes the entire sequence of exon 1 and should subsequently 
result in complete loss of protein expression.  In both patients the presence of the 
mutation was confirmed based on sequencing the deletion endpoints after PCR 
amplification of genomic DNA (data not shown).  Additionally, we report a novel 
single-base deletion c.641delG found in a previously reported patient from 
Belarus together with the previously identified missense mutation p.C76F 
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[Hrebicek et al., 2006] and a single base insertion, c.1271dupG.  This latter 
mutation was found in two patients from Greece, in combination with the 
missense mutation p.S541L in one, and with p.E471K in the other.  
 
Nonsense mutations 
 The introduction of a PTC via a single nucleotide base change was 
previously thought to result in the synthesis of a truncated protein, however 
recent research has shown that PTC-carrying transcripts are rapidly degraded via 
the nonsense-mediated mRNA decay (NMD) pathway protecting the cell from 
potentially harmful effects of truncated proteins [Muhlemann et al., 2008; 
McGlincy and Smith, 2008].  Six nonsense mutations in the HGSNAT gene have 
thus far been described in the literature.  Our first report included 4 nonsense 
mutations: p.W316X, p.L321X, p.R384X and p.R506X.  The latter mutation was 
found in 10 patients, 5 of which were Polish, the others being from the rest of 
Europe and North America. Ruijter et al. [2007] reported two nonsense 
mutations, p.R203X and p.W510X, present in heterozygosis in patients of Dutch 
ancestry.  We report here 2 novel nonsense mutations: p.S296X was found in 
homozygosis in one UK patient of Pakistani ancestry and p.Y558X was found in 
heterozygosis with c.1542+4dupA in another UK patient.  Parental DNA or 
patient cDNA were not available for sequencing confirmation. 
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Missense mutations 
 Missense mutations, causing amino acid changes comprise the majority of 
the MPS IIIC mutations identified to date, with 16 mutations already reported in 
the literature.  Here we present 2 novel mutations: p.G486E found in 
homozygosis in a German patient and p.A489E found in a patient from the USA. 
The p.A489E mutation was confirmed in maternal allele, but no parental DNA or 
patient cDNA was available to confirm the p.G486E change. 
Phenotypic pathogenicity of missense mutations is difficult to predict 
based strictly on genotype, so expression of the mutant proteins is normally 
required to understand the effect of the amino acid change on folding, targeting, 
stability and activity of the enzyme.  Since no such studies have been reported so 
far, we evaluated here (Table 1) potential changes of the native protein structure 
caused by the mutations based on the nature of the amino acid, its evolutionary 
conservation and position within the protein. Eight missense mutations, p.G262R, 
p.P283L, p.W403C, p.M482K, p.G486E, p.A489E, p.S518F, and p.P571L are 
predicted to reside within the highly hydrophobic transmembrane domains of the 
protein.  Five of these mutations introduce hydrophilic or charged residues inside 
the transmembrane domains potentially affecting folding of the protein [reviewed 
in Gregersen et al., 2001] and drastically reducing its activity.  Four other changes 
result in replacement of hydrophilic residues for hydrophobic ones that also could 
destabilize the transmembrane helix. Six mutations are found adjacent to the 
predicted transmembrane domains either on the cytoplasmic (p.D562V) or on the 
lumenal (p.R344C/H, p.E471K, p.S539C, p.S541L) side and 4 mutations 
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(p.C76F, p.L137P, p.N273K, p.G424S) reside inside the hydrophilic lumenal 
domains of the enzyme.  These mutations may affect areas important for binding 
of AcCoA, its transport through the lysosomal membrane or for the catalytic 
activity of the enzyme, and therefore knowledge of the protein structure is 
required for understanding their effects.   
 
Polymorphisms 
Previously [Hrebicek et al. 2006] we have described so-called complex 
mutations in the HGSNAT gene, consisting either of a splice site mutation found 
in cis with a missense mutation or of two missense mutations in cis.  In particular, 
the combination of mutations c.234+1G>A and p.P237Q was identified in three 
patients of Moroccan origin and in one patient from Spain, the combination of 
c.493+1G>A and p.K523Q was identified in a patient of Algerian origin and the 
combination of p.W403C and pA615T was identified in a patient from the UK 
and a patient from France.  Of note, the mutation c.493+1G>A was also identified 
in four other patients, one from Canada and one from Singapore, but without the 
presence of the accompanying p.K523Q change, whereas the mutation 
c.234+1G>A without accompanying p.P237Q was found in patients from France, 
Italy and Turkey.  The missense mutation p.V481L was identified in a patient 
from the UK together with a splice site mutation c.1542+4dupA and the nonsense 
mutation p.Y558X. 
 At the time of publication it was difficult to deduce which of these 
missense mutations identified as a part of complex mutations could be classified 
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as polymorphisms and which represented a clinically relevant genotype, although 
later we have identified a c.1843G>A (p.A615T) change present in heterozygosis 
in one normal control DNA sample.  In an effort to resolve this issue we have 
evaluated effects of the above amino acid changes on the activity of HGSNAT by 
expressing the enzyme carrying these changes in COS-7 cells.  While p.P237Q, 
p.V481L, p.K523Q and p.A615T mutants had enzymatic activity similar to that 
of the wild type HGSNAT, the p.W403C mutant completely lost its activity (data 
not shown).  These data likely suggest that amino acid changes p.P237Q, 
p.V481L, p.K523Q and p.A615T are rare polymorphisms and do not have clinical 
significance. 
 
CLINICAL AND DIAGNOSTIC RELEVANCE 
Although the spectrum of mutations in MPS IIIC patients shows high 
heterogeneity, some identified mutations have high frequency within a population 
or even across populations suggesting founder effects.  First, a comprehensive 
study in MPS IIIC patients [Ruijter et al., 2007] has shown founder effects in the 
Dutch population where the two mutations p.R344C and p.S518F account for 
22.0% and 29.3% respectively, of the alleles among the probands of Dutch origin.  
p.S518F mutation has been identified so far only in Dutch patients and in one 
patient from Germany, while the p.R344C change was also found in families 
from France, UK, Germany and Singapore.  Fedele et al. [2007] showed that 
probands from 3 of the 10 studied families were homozygous for the mutation 
c.852-1G>A, and that all these patients had origins in southern Italy [Fedele et al., 
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2007].  The same mutation was also found in a family from Turkey.  Finally, the 
mutation c.525dupT reported by Countinho et al. [2008] was found in five out of 
six alleles of MPS IIIC patients from Portugal, also suggesting a possible founder 
effect.  In support of this we report here 2 different Portuguese patients each 
possessing the c.525dupT mutation in homozygosis.  The high frequencies of the 
above mutations suggest that molecular analysis can be a valid diagnostic option 
for MPS IIIC patients of Dutch, Portuguese and Italian origin.  
Several other mutations showing a relatively high frequency among the 
MPS IIIC families are also characterized by wide distribution which doesn’t 
suggest a founder effect in any particular population but rather a global founder 
effect of an ancient mutation.  For example, p.R384X mutation was found in both 
homo- and heterozygous fashion in 10 patients from 6 different countries 
(Poland, Czech Republic, Italy, The Netherlands, Canada and Turkey).  Similarly, 
the most common splice site mutation, c.234+1G>A, is present in 7 patient 
families, one from France, one from Italy, one from Spain, one from Turkey, two 
from Morocco and one from Canada where both parents are of Moroccan origin.  
The second most common splice site mutation c.493+1G>A was reported in 3 
Canadian families, one family from Algeria and one from Singapore.  The point 
mutation p.R344H was found in 4 families from Eastern and Northern Europe (2 
from Poland, one from Czech Republic and one from Finland).  This mutation 
and the Dutch founder mutation p.R344C are caused by changes of the 
neighbouring nucleotides, c.1031 and c.1030, respectively, and affect the same 
amino acid residue.  Finally, missense mutation p.S541L was reported in 4 
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families from France, Ireland, Poland and Portugal. As all mutations discussed in 
this paragraph change C to T or G to A in a CpG dinucleotide, it is also possible 
that they arose independently in different populations due to deamination of 
methylcytosine.  All other mutations have only been found in one to three 
families. 
The majority of MPS IIIC patients described so far show severe clinical 
phenotype accompanied by a complete or almost complete loss of N-
acetyltransferase activity in their leukocytes or cultured skin fibroblasts.  
Therefore, no genotype-phenotype correlations or predictions of clinical outcome 
of the mutations can be reported at this point with an exception of the mutations 
p.G262R and p.S539C that probably correlate with an attenuated MPS III 
phenotype as they were only found in two sisters with late-onset form of the 
disease [Ruijter et al., 2007; Berger-Plantinga, 2004].  In addition, we have 
identified a splice site mutation c.118+1G>A and one missense mutation p.S541L 
in 3 sisters of Irish ancestry affected with a late-onset MPS IIIC, but it is 
impossible to confirm at this point whether p.S541L results in partially functional 
protein or whether a part of mRNA produced by the c.118+1G>A allele is 
correctly spliced.  
Presently no studies have been reported addressing the effect of detected 
mutations in the HGSNAT gene locus on the enzyme activity, stability, 
localization, processing and ability to interact with other proteins.  Such studies 
especially important in the case of missense mutations will allow to clarify the 
pathogenic mechanism of MPS IIIC, establish the correlations between the type 
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of mutation and severity of the biochemical and clinical phenotype useful for 
clinical prognosis and may also suggest novel therapeutic approaches.  Such 
studies may also shed light on the molecular structure and function of the enzyme 
since naturally occurring mutations are known to cause the clinically significant 
deficiency of the enzyme and therefore appear in functionally important areas.   
In the vast majority of patients at least one missense mutation affects an 
amino acid residue in or adjacent to the transmembrane domains of HGSNAT, 
probably interfering with the proper folding of the enzyme.  If the expression 
studies confirm this hypothesis, active site-specific inhibitors of the enzyme could 
be tested for their ability to stabilize the mutants and modify their conformation 
closer to that of the wild type enzyme increasing the level of their residual 
activity as it has been demonstrated for other lysosomal enzymes [reviewed in 
Fan, 2003; Desnick, 2004].  Together with the inhibitors of heparan sulfate 
synthesis [Piotrowska et al., 2006; Jakóbkiewicz-Banecka et al., 2007], such 
“pharmacological chaperones” could probably be an interesting subject of future 
research in this area.  
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Table I.  Mutations in the HGSNAT Gene* 
Nucleotide changea Predicted effect  on protein Exon Effect Origin Reference 
Splicing site mutations 
c.118+1G>A  Intron 1  Irelandb Hřebíček et al. [2006] 
France, Morocco, 
Spain 
Hřebíček et al. 
[2006] 
Italy Fedele et al. [2007] c.234+1G>A p.D40VfsX19
c Intron 2  
Morocco, Turkey Ruijter et al. [2008] 
c.372-2A>G  Intron 3 Skipping of exon 4 Portugal Coutinho et al. [2008] 
Canada Fan et al. [2006] 
Algeriad, Canada Hřebíček et al. [2006] c.493+1G>A  Intron 4  
Singapore This report 
c.743+1dupG p.I249DfsX31 Intron 7  Netherlands Ruijter et al. [2008] 
c.744-2A>G  Intron 7  Pakistan This report 
c.851+5G>A p.F285Xc Intron 9 
Inclusion of 89 
bases from 5’end 
of intron 9, 
skipping of exon 
10. PTC 
Czech Republic  Hřebíček et al. [2006] 
Italy Fedele et al. [2007] c.852-1G>A  Intron 9  Turkey This report 
Poland Hřebíček et al. [2006] c.1250+1G>A  Intron 12  Turkey, UK This report 
c.1250+2T>C  Intron 12  USA This report 
c.1464+1G>A  Intron 14  Italy Fedele et al. [2007] 
c.1542+4dupA  Intron 15  UK This report 
c.1726+1G>A p.S539NfsX14c Intron 17 
Skipping of exon 
17, frameshift Turkey 
Hřebíček et al. 
[2006] 
Ruijter et al. [2008] 
Insertions and deletions 
c.1-1925_118+296del  1 2339 bp deletion including  exon 1 Turkey This report 
c.525dupT p.V176CfsX16 5  Portugal Coutinho et al. [2008] 
c.641delG p.Gly214AspfsX62 7  Belarus This report 
c.682_740del p.P228GfsX32 7  Italy Fedele et al. [2007] 
Italy Fedele et al. [2007] c.739delA p.R247GfsX29 7  North Africa This report 
c.1034_1049del p.I345SfsX5 11  Czech Republic Hřebíček et al. [2006] 
c.1271dupG p.I425HfsX45 13  Greece This report 
c.1336_1372dup p.V460GfsX22 13  Poland Hřebíček et al. [2006] 
c.1345dupG p.D449GfsX21 13  Canada Fan et al. [2006] 
c.1669_1674delinsAC
AT p.L557TfsX33 17  Italy Fedele et al. [2007] 
c.1750delG p.V584SfsX16 18  Finland Hřebíček et al. [2006] 
Nonsense mutations 
c.607C>T p.R203X 6 PTC Netherlands Ruijter et al. [2008] 
c.887C>A p.S296X 10 PTC Pakistan This report 
c.947G>A p.W316X 10 PTC France Hřebíček et al. [2006] 
c.962T>G p.L321X 10 PTC Czech Republic Hřebíček et al. [2006] 
c.1150C>T p.R384X 12 PTC 
Canada, Czech 
Republic,  Poland, 
Turkey 
Hřebíček et al. 
[2006] 
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Italy Fedele et al. [2007] 
Netherlands, Turkey Ruijter et al. [2008] 
Czech Republic Hřebíček et al. [2006] c.1516C>T p.R506X 15 PTC 
Belgium This report 
c.1530G>A p.W510X 15 PTC Netherlands Ruijter et al. [2008] 
c.1674C>G  p.Y558X  17 PTC UK This report 
Missense mutations 
c.227G>T p.C76F 2 
Changes a polar 
residue for a non-
polar in the 
lysosomal lumen  
Belarus Hřebíček et al. [2006] 
Netherlands 
 
Ruijter et al. [2008]; 
 Fedele et al. 
[2007] c.410T>C p.L137P 4 
Changes a highly 
hydrophobic 
residue for a 
hydrophilic one in 
the lysosomal 
lumen  
Germany This report 
c.784G>A p.G262R 8 
Changes a neutral 
non-polar 
hydrophobic 
residue for a 
strongly basic 
polar hydrophilic 
one in the 
membrane  
Netherlands Ruijter et al. [2008] 
c.819T>G p.N273K 8 
Changes a neutral 
residue for a basic 
in the lysosomal 
lumen 
Netherlands Ruijter et al. [2008] 
France, UK Hřebíček et al. [2006] c.848C>T p.P283L 9 
Changes a 
hydrophilic residue 
for a hydrophobic 
in the membrane Turkey This report 
France, UK Hřebíček et al. [2006] 
Netherlands  Ruijter et al. [2008] 
c.1030C>T p.R344C 11 
Changes a 
strongly basic and 
highly hydrophilic 
residue for a 
neutral and highly 
hydrophobic one 
just inside the 
lysosomal lumen  
Germany, Singapore This report 
c.1031G>A p.R344H 11 
Changes a 
strongly basic 
residue for a 
weakly basic just 
inside the 
lysosomal lumen 
Czech Republic, 
Finland,  Poland 
Hřebíček et al. 
[2006] 
 
France  Hřebíček et al. [2006] 
c.1209G>T p.W403C 12 
Changes a non-
polar hydrophilic 
residue to a 
neutral 
hydrophobic one in 
membrane 
UK This report 
c.1270G>A p.G424S 13 
Changes a non-
polar residue for a 
polar in the 
lysosomal lumen 
Canada Hřebíček et al. [2006] 
Canada, France Hřebíček et al. [2006] 
Netherlands Ruijter et al. [2008] c.1411G>A p.E471K 14 
Changes an acidic 
residue for a basic 
just inside the 
lysosomal lumen  Greece This report 
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c.1445T>A p.M482K 14 
Changes a non-
polar neutral 
hydrophobic 
residue for a polar 
basic hydrophilic 
one inside the 
membrane  
Czech Republic Hřebíček et al. [2006] 
c.1457G>A p.G486E 14 
Changes  neutral 
non-polar 
hydrophobic 
residue for a a 
polar acidic 
hydrophilic one 
inside the 
membrane    
Germany This report 
c.1466C>A  p.A489E 15 
Changes a non-
polar neutral 
hydrophobic 
residue for a polar 
acidic hydrophilic 
one inside the 
membrane 
USA This report 
Netherlands 
 
Fedele et al. [2007]; 
 Ruijter et al. 
[2008] c.1553C>T p.S518F 16 
Changes a polar 
hydrophilic residue 
for a non-polar 
hydrophobic one 
inside the 
membrane 
Germany This report 
c.1616C>G p.S539C 17 
Changes a 
hydrophilic residue 
for a hydrophobic 
inside the 
lysosomal lumen 
Netherlands Ruijter et al. [2008] 
France, Irelandb, 
Poland,  
 Portugal,  
Hřebíček et al. 
[2006] 
 c.1622C>T p.S541L 17 
Changes a polar 
hydrophilic residue 
for a non-polar 
hydrophobic one 
just inside the 
lysosomal lumen 
Greece This report 
c.1685A>T p.D562V 17 
Changes a polar 
acidic highly 
hydrophilic residue 
for a non-polar 
neutral highly 
hydrophobic one in 
the cytoplasm 
France Hřebíček et al. [2006] 
c.1712C>T p.P571L 17 
Changes a 
hydrophilic residue 
for a hydrophobic 
in the membrane 
Czech Republic Hřebíček et al. [2006] 
Polymorphisms 
Morocco, Spain Hřebíček et al. [2006] c.710C>A p.P237Q 7 
Changes a non-
polar for a polar 
residue in the 
cytoplasm Morocco Ruijter et al. [2008] 
c.1441G>T p.V481L 14 Conservative residue change UK This report 
c.1567A>C p.K523Q 16 
Changes a basic 
residue for a 
neutral just inside 
the lysosomal 
lumen 
Algeriad Hřebíček et al. [2006] 
France Hřebíček et al. [2006] 
c.1843G>A p.A615T 18 
Changes a non-
polar hydrophobic 
residue for a polar 
hydrophilic one 
inside the 
membrane 
UK This report 
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Table 1.*Novel mutations and patients are shown in bold. The following mutation was 
renamed according to the Human Genome Variation Society: c.743+1insG to 
c.743+1dupG 
a The numbering for the nucleotide changes are based on cDNA sequence in accordance 
with GenBank entries NM_152419.2 and NG_009552.1, with +1 corresponding to the A 
of the ATG translation initiation codon in the reference sequence.  
bPatient carrying this mutation originally published as from USA in Hřebíček et al. [2006] 
cEffect confirmed by cDNA sequencing.  
dPatient carrying this mutation originally published as from France in Hřebíček et al. 
[2006]. PTC, premature termination codon 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65
Figure 1. Distribution of missense mutations in HGSNAT protein.  Visual 
representation of HGSNAT membrane topology was created using the 
TMRPres2D software [Spyropoulos et al. 2004].  Mutated residues are shown in 
white letters on black background and predicted N-glycosylation sites are boxed. 
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Figure 2. Location of MPS IIIC mutations in the HGSNAT gene. The exons 
are represented by boxes.  The positions of the missense mutations are shown 
above the gene.  Other mutations (nonsense, insertions, deletions and splice-site 
mutations) are shown below the gene.  Nonsense and missense mutations are 
presented based on amino acid changes, while splice-site mutations, insertions 
and deletions are presented based on nucleotide changes.  Novel mutations are 
shown in bold.  
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CHAPTER 3 
 
 
 
 
 
 
 
 
 
Characterization of molecular defects in HGSNAT gene 
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Foreword 
 
MPS IIIC patients with missense mutations experience a severe disease 
progression similar to patients with mutations predicted to result in the complete 
absence of protein. In order to understand the effects these mutations have on the 
enzyme we expressed HGSNAT mutants containing each of the 17 reported 
missense mutations and 4 polymorphisms and examined their enzymatic activity, 
targeting and folding. 
 We determined that all the missense mutations caused HGSNAT to be 
misfolded. Furthermore we showed the HGSNAT missense mutants to be 
inactive, abnormally glycosylated and retained in the ER. We then identified 
glucosamine as a competitive inhibitor of HGSNAT, and showed that it was able 
to rescue activity in 8 of 9 patient fibroblast lines.  
These studies utilized transient expression, enzyme assay, immunoblot 
and immunocytochemistry analyses.  
 
All experiments as well as preparation of the manuscript was conducted by 
Matthew Feldhammer, with the exception of the mutants’ generation and cloning, 
determination of the substrate kinetics and the glucosamine inhibition constant.  
 
*Article published in PLOS One Journal following peer review 
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ABSTRACT 
 
 Mucopolysaccharidosis type IIIC or Sanfilippo syndrome type C (MPS 
IIIC, MIM #252930) is an autosomal recessive disorder caused by deficiency of 
the lysosomal membrane enzyme, heparan sulfate acetyl-CoA: α-glucosaminide 
N-acetyltransferase (HGSNAT, EC 2.3.1.78), which catalyses transmembrane 
acetylation of the terminal glucosamine residues of heparan sulfate prior to their 
hydrolysis by α-N-acetylglucosaminidase.  Lysosomal storage of undegraded 
heparan sulfate in the cells of affected patients leads to neuronal death causing 
neurodegeneration and is accompanied by mild visceral and skeletal 
abnormalities, including coarse facies and joint stiffness.  Surprisingly, the 
majority of MPS IIIC patients carrying missense mutations are as severely 
affected as those with splicing errors, frame shifts or nonsense mutations 
resulting in the complete absence of HGSNAT protein. 
In order to understand the effects of the missense mutations in HGSNAT 
on its enzymatic activity and biogenesis we have expressed 21 mutant proteins in 
cultured human fibroblasts and COS-7 cells and studied their folding, targeting 
and activity.  We found that 17 of the 21 missense mutations in HGSNAT caused 
misfolding of the enzyme, which is anbormally glycosylated and not targeted to 
the lysosome, but retained in the endoplasmic reticulum.  The other 4 mutants 
represented rare polymorphisms which had no effect on the activity, processing 
and targeting of the enzyme.  Treatment of patient cells with a competitive 
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HGSNAT inhibitor, glucosamine, partially rescued several of the expressed 
mutants. 
Altogether our data provide an explanation for the severity of MPS IIIC 
and suggest that search for pharmaceutical chaperones can in the future result in 
therapeutic options for this disease.
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AUTHOR SUMMARY 
 
Mucopolysaccharidosis III type C (MPS IIIC) belongs to a group of 
genetic metabolic diseases affecting the lysosome, a cellular compartment 
responsible for degradation and recycling of biological macromolecules.  
Lysosomal diseases comprise ~14% of all inherited diseases of metabolism and, 
although individually rare, together they affect one of every 7700 newborn 
children [1].  MPS IIIC causes rapid progressive neurodegeneration in infants and 
children, accompanied by variable problems of the eyes, bones and viscera.  Our 
current study provides an explanation for the severity of the disease.  We showed 
that in the patient cells the lysosomal enzyme called N-acetyltransferase contains 
amino acid substitutions that prevent its normal folding, processing and 
trafficking. We also showed that a small competitive inhibitor of the N-
acetyltransferase can partially restore the folding, trafficking and activity of 
several mutants which may provide future therapeutic solutions for this 
devastating untreatable disease.  
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INTRODUCTION  
 
Mucopolysaccharidosis III (also called Sanfilippo syndrome) is an 
autosomal recessive disease caused by lysosomal accumulation of heparan sulfate 
[reviewed in 2] and includes four allelic subtypes caused by the genetic 
deficiencies of heparan N-sulfatase (MPS III type A; MIM #252900), α-N-
acetylglucosaminidase (MPS III type B; MIM #252920), heparan sulfate acetyl-
CoA: α-glucosaminide N-acetyltransferase or HGSNAT (MPS III type C; MIM 
#252930), and N-acetylglucosamine 6-sulfatase (MPS III type D; MIM 
#252940).  The majority of MPS IIIC patients have severe clinical manifestations 
with onset in infancy or early childhood.  They rapidly develop progressive and 
severe neurological deterioration causing hyperactivity, sleep disorders, loss of 
speech accompanied by behavioral abnormalities, neuropsychiatric problems, 
mental retardation, hearing loss, and visceral manifestations, such as mild 
hepatomegaly, mild dysostosis multiplex, mild coarse facies, and hypertrichosis 
[3,4].  A majority of patients experience severe mental retardation and die before 
adulthood but some survive to the fourth decade with progressive dementia and 
retinitis pigmentosa [2,4].  In the very rare MPS IIIC patients with the onset of 
symptoms in adulthood the disease progression was similar in severity and time 
course to the forms with onset in childhood [5].  The birth prevalence of MPS 
IIIC in Australia, Portugal and the Netherlands was estimated at 0.07, 0.12 and 
0.21 per 100,000, respectively [1,6,7]. 
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Although from the moment of discovery MPS IIIC was recognized as a 
deficiency of an enzyme that transfers an acetyl group from cytoplasmically 
derived acetyl-CoA to terminal N-glucosamine residues of heparan sulfate within 
the lysosomes [8-10], the molecular defects causing the disease have not been 
characterized for almost three decades because the identification and cloning of 
HGSNAT has been hampered by low tissue content and instability of the enzyme.  
Recently our group and others cloned the gene coding for HGSNAT [11,12] 
which paved the way for characterization of the molecular defects in MPS IIIC 
patients. To date, 54 HGSNAT sequence variants have been identified including 
13 splice-site mutations, 11 insertions and deletions causing frame shifts and 
premature termination of translation, 8 nonsense, 18 missense mutations and 4 
polymorphisms [reviewed in 13, 
http://chromium.liacs.nl/LOVD2/home.php?select_db=HGSNAT].  While the 
HGSNAT transcripts with abnormal splicing, frame shifts and premature stop 
codons are rapidly degraded via the nonsense-mediated mRNA decay pathway 
[11], the phenotypic pathogenicity of missense mutations was impossible to 
predict.  Here, in order to understand the biochemical effects of the missense 
mutations we have expressed mutant proteins in cultured human fibroblasts and 
COS-7 cells and found that all mutations result in misfolding of the enzyme.  In 
the consequence, it is abnormally glycosylated, and is not targeted to the 
lysosome, but retained in the endoplasmic reticulum (ER).   
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RESULTS   
 
Expression, processing and enzymatic activity of HGSNAT mutants 
The effect of HGSNAT mutations on the enzyme biogenesis and catalytic 
activity was studied by the transient expression of the mutant cDNA. Mutations 
were generated by site directed mutagenesis in the pCTAP-HGSNAT construct 
that expresses human HGSNAT with a C-terminal tandem affinity purification 
(TAP) tag consisting of a high affinity streptavidin-binding peptide (SBP) and a 
calmodulin-binding peptide (CBP) to allow purification of the recombinant 
protein using successively-applied streptavidin-resin and calmodulin-resin 
affinity purification steps or its detection with anti-CBP antibodies [14,15].  In 
preliminary experiments we have ensured that a human wild-type HGSNAT 
carrying a TAP tag on its C-terminus had a lysosomal localization and showed 
catalytic activity similar to that of the untagged enzyme (not shown). The 
sequences of the constructs were verified to ensure the correct introduction of 
mutations. In total, 21 constructs bearing nucleotide changes identified in patients 
were transfected in COS-7 cells and assayed for the N-acetyltransferase activity 
(Figure 1).  All tested cells showed similar endogenous lysosomal β-
hexosaminidase activity (not shown) but drastically different levels of the N-
acetyltransferase activity.  The four polymorphisms (P237Q, V481L, K523Q and 
A615T) displayed activity similar to that of the wild-type enzyme, whereas the 
activity of the rest of the mutants was below the detection level.  Kinetics studies 
were further conducted using partially purified enzyme to determine if the P237Q 
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and V481L mutants showing full enzymatic activity would have a different 
affinity for the substrate, however their Km and Vmax values were similar to those 
of the wild-type (Supplementary figure 1, Appendix I).   
The expression of HGSNAT mutants was studied by Western blot 
analysis of cellular homogenates using anti-CBP antibodies (Figure 1B).  All 
mutants were expressed at a level approximately similar to that of the wild-type 
HGSNAT, but showed a difference in their molecular mass. The four 
polymorphisms (P237Q, V481L, K523Q and A615T) showed a molecular mass 
of ~77 kDa, similar to that of the wild-type enzyme, whereas all missense 
mutants (C76F, L137P, G262R, N273K, P283L, R344C, R344H, W403C, 
G424S, E471K, M482K, A489E, S518F, S539C, S541L, D562V, P571L) had a 
smaller molecular mass of ~67 kDa.  Since HGSNAT is predicted to have 5 
potential N-linked glycosylation sites each potentially contributing ~2 kDa to the 
size of the mature enzyme [11], this molecular mass difference was consistent 
with the hypothesis that inactive mutants lacked proper glycosylation. To confirm 
this, the wild-type enzyme, 2 polymorphic variants and 2 inactive mutants were 
treated with endoglycosidase H which cleaves immature mannose-rich 
oligosaccharide chains added to glycoproteins in the ER [16]  Analysis by 
Western blot (Figure 2) showed that upon deglycosylation the molecular mass of 
the wild-type enzyme and polymorphic mutants was reduced to 67 kDa, whereas 
the inactive mutants displayed only a subtle shift in their position on the gel, 
indicating that they already lacked most of the glycans.  The homogenates were 
also treated with the peptide: N-Glycosidase F (PNGase F) which fully removes 
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all sugars from mature glycoproteins (Figure 2B).  In addition to performing 
enzymatic deglycosylation of cell homogenates we treated the COS-7 cells 
transiently expressing the wild-type enzyme, a polymorphic and an inactive 
mutant with tunicamycin, an inhibitor of N-acetylglucosamine transferase that 
blocks glycosylation of newly-synthesized proteins (Figure 2C). Results of both 
experiments were consistent with those obtained with Endoglycosidase H.  Upon 
the treatment with tunicamycin or PNGase F the size of the wild type HGSNAT 
and the enzyme containing the polymorphism was reduced by approximately ~10 
kDa whereas the inactive mutant displayed only a minor change in 
electrophoretic mobility.  Western blot analysis also revealed that the 
homogenates of the cells transfected with both wild-type HGSNAT and 
polymorphic mutants, but not of untransfected cells or cells transfected with 
inactive mutants contained an immunoreactive protein with a molecular mass of 
~48 kDa.  Since this form of HGSNAT contains the C-terminal CBP cross-
reacting with the antibodies we estimated that it corresponds to the HGSNAT 
fragment missing ~300 amino acids on the N-terminus.  It seems that the 
appearance of this form is associated with the proper glycosylation and lysosomal 
targeting of HGSNAT, but further studies are necessary to conclude whether it 
represents a product of intralysosomal maturation (with the N-terminal chain not 
being detected by our antibodies) or a degradation product.  On the other hand, 
the 77-kDa form of HGSNAT separated by FPLC anion-exchange 
chromatography showed full enzymatic activity (Figure 3).   
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Subcellular localization of HGSNAT mutants 
The effects of missense mutations on the subcellular localization of the 
enzyme were studied by confocal immunofluorescence microscopy. Immortalized 
human skin fibroblasts from a normal control were transfected with constructs 
expressing each of the missense mutations. The cells were allowed to express the 
mutant and polymorphic enzymes for 42 hours and were then fixed by 
paraformaldehyde.  To identify the lysosomal-late endosomal compartment, prior 
to fixation the cells were treated with LysoTracker Red DND-99 dye.  After 
fixation the cells were permeabilized with Triton X-100 and probed with anti-
CBP antibodies to localize the HGSNAT and with antibodies against the ER 
marker calnexin and lysosomal marker LAMP-2. 
Distinct punctate staining characteristic of lysosomal targeting of the 
protein was evident for the recombinant wild-type enzyme and all active mutants.  
Accordingly, both wild-type recombinant HGSNAT and polymorphic mutants 
almost completely co-localized with the lysosomal markers LysoTracker Red or 
LAMP-2 (representative data are shown in Figure 4). In contrast, the inactive 
mutants exhibited a diffuse pattern throughout the cell and were co-localized not 
with the lysosomal markers but with the ER marker calnexin (representative data 
are shown in Figure 4, see Supplementary figure 2 for the data on all mutants, 
Appendix II).  Partial ER localization (typically 2-5% of the total, not shown) was 
also observed for the wild-type recombinant and active mutants and most likely 
represented a pool of the enzyme processed in the ER on its way to the 
lysosomes.   
 81
 
Glucosamine-mediated refolding of inactive HGSNAT mutants 
Since all the data were consistent with general folding defects and 
retention in the ER compartment of the HGSNAT mutants (C76F, L137P, 
G262R, N273K, P283L, R344C, R344H, W403C, G424S, E471K, M482K, 
A489E, S518F, S539C, S541L, D562V, P571L) we further tested whether 
competitive inhibitors of the enzyme that mimic the substrate binding in the 
active site would help to fold the enzyme in the ER so it can be properly modified 
and exported to the lysosome.  We first tested several potential inhibitors of 
HGSNAT that were not expected to be highly toxic for the cultured cells and 
found that one of them, D-(+)-glucosamine hydrochloride, was a competitive 
inhibitor of the enzyme with a KI of 0.28 mM close to the KM value for the 4MU-
βGlcN substrate (Supplementary figure 3, Appendix III).  To establish the 
optimal concentration of the inhibitor in the culture medium and the length of the 
treatment, we have used the immortalized skin fibroblasts of previously reported 
MPS IIIC patient homozygous for the N273K mutation that causes misfolding of 
the enzyme (Figure 1 and Figure 4), since they were readily available in our lab 
[25].  Immortalized fibroblasts from a patient homozygous for a splice site 
mutation (c.1726+1G>A) [11] and normal immortalized fibroblasts were used as 
controls.  We found that the treatment of fibroblasts from a patient homozygous 
for the N273K mutation with 14 mM glucosamine results in the progressive 
increase of the N-acetyltransferase activity in the cell homogenates which reaches 
3 fold induction after 5 days of treatment (Figure 5A).  The N-acetyltransferase 
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activity in the normal cells and in the cells of the MPS IIIC patient homozygous 
for the splice site mutation c1726+1G>A as well as the control β-hexosaminidase 
activity in all cell lines were not increased upon the treatment (not shown) 
suggesting that the observed induction of N-acetyltransferase activity was caused 
by rescuing the N273K mutant but not by the general induction of lysosomal 
enzymes.  When the cells of the patient affected with the N273K mutation were 
treated for 5 days with increasing concentrations of glucosamine (Figure 5B) we 
found that the effect was proportional to the concentration of the inhibitor.  At the 
glucosamine concentration of 14 mM (~50x KI) the N-acetyltransferase activity 
in the treated cells was 0.3 nmol/h mg which corresponds to ~7% of the average 
activity in normal control fibroblasts, but further increase of glucosamine 
concentration resulted in inhibition of cell growth.  To understand whether 
similar effects could be also observed for other missense mutants the available 
primary cultures of skin fibroblasts from 9 MPS IIIC patients carrying missense 
HGSNAT mutations or a missense mutation in combination with a splice site or 
nonsense mutation were treated with glucosamine and assayed for N-
acetyltransferase activity.  Nine missense mutations were studied altogether 
(Figure 5C; patient genotypes are listed in the figure legend).  Although the 
maximal effect for different cell lines was achieved at different concentrations of 
glucosamine and at different treatment time (not shown), for 8 of 9 cell lines a 
statistically significant increase in the activity was observed (Figure 5C), 
suggesting that some of the mutants were partially stabilized by the glucosamine, 
correctly processed and targeted to the lysosomal compartment.  
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DISCUSSION 
 
The current work provides an explanation for the severe phenotype of 
MPS IIIC patients carrying missense mutations in the HGSNAT gene.  Altogether, 
we studied the activity and biogenesis of HGSNAT mutants having 21 amino 
acid substitutions previously identified in MPS IIIC families and affecting 8 of 
the 11 transmembrane segments of the enzyme as well as its luminal and 
cytosolic domains (Figure 6).  The missense mutations studied in this paper 
represent all of the currently identified missense HGSNAT mutations. The 
polymorphisms  (P237Q, V481L, K523Q and A615T, shown in green in Figure 
6) identified in MPS IIIC only in cis either with a splice site mutation or with a 
missense mutation [11,13] were previously reported by us to result in 
catalytically active protein [13].  They were included in the current study because 
it was unclear whether they still could affect kinetic parameters or targeting of 
HGSNAT and therefore represent a clinically valuable phenotype.  All variants 
were expressed as TAP-tagged proteins since no Western blotting or cellular 
immunostaining could be conducted using the patient fibroblasts due to a lack of 
specific antibodies against human HGSNAT.  Our results show that the 
HGSNAT variants P237Q, V481L, K523Q and A615T are all correctly processed 
targeted to the lysosome and display full enzymatic activity.  We conclude 
therefore that these four mutations represent rare polymorphisms in the HGSNAT 
gene and do not have clinical significance thus confirming our previous 
hypothesis [13].  
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Seventeen mutations (C76F, L137P, G262R, N273K, P283L, R344C, 
R344H, W403C, G424S, E471K, M482K, A489E, S518F, S539C, S541L, 
D562V and P571L, shown in red in Figure 6) result in production of misfolded 
HGSNAT protein that is abnormally glycosylated and not targeted to the 
lysosome.  Seven of these mutations (G262R, P283L, W403C, M482K, A489E, 
S518F and P571L) are predicted to reside within the highly hydrophobic 
transmembrane domains of the protein.  Four of them (G262R, W403C, M482K, 
A489E) introduce hydrophilic or charged residues inside the transmembrane 
domains which usually have a dramatic effect on the folding of the protein 
[reviewed in 18].  Three other changes (P283L, S518F and P571L) result in 
replacement of hydrophilic residues for hydrophobic ones that also could 
destabilize the transmembrane helix.   
Six mutations (R344C, R344H, E471K, S539C, S541L and D562V) are 
found adjacent to the predicted transmembrane domains either on the cytoplasmic 
(D562V) or on the lumenal (R344C, R344H, E471K, S539C, and S541L) side 
and 4 mutations (C76F, L137P, N273K, and G424S) reside inside the hydrophilic 
lumenal domains of the enzyme.  In most cases these mutations are predicted to 
have a drastic effect on the protein folding since they involve replacements with 
amino acids significantly different in hydrophobicity (C76F, D562V, S541L), 
charge (R344C/H, N273K, E471K) or size (C76F, L137P, G424S).  Thus, 
enzyme folding defects due to missense mutations, together with nonsense-
mediated mRNA decay seem to be the major molecular mechanisms underlying 
MPS IIIC.    
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For at least 5 of the above changes (N273K, R344C, R344H, S518F and 
S541L) the active conformation can be stabilized by the competitive inhibitor of 
HGSNAT glucosamine resulting in part of the enzyme pool being properly 
processed and targeted to the lysosomes.  L137P and P283L mutants may also be 
stabilized by the glucosamine treatment, however this could not be verified 
experimentally because in the available patient cell lines they were present 
together with the responsive mutations S518F and R344C, respectively.  Only 
one cell line carrying E471K and D562V mutations did not show a significant 
increase in N-acetyltransferase activity in response to glucosamine.  Further 
structural studies are needed to fully understand the difference in the effect of 
glucosamine on these mutants.   
Although the spectrum of mutations in MPS IIIC patients shows 
substantial heterogeneity, some of the missense mutations have a high frequency 
within the patient population.  Importantly, the two mutations, R344C and S518F, 
responsive to glucosamine-mediated refolding account for 22.0% and 29.3%, 
respectively, of the alleles among the probands of Dutch origin [19]. The S518F 
mutation has also been identified in a patient from Germany, while the R344C 
change was found in families from France, UK, Germany and Singapore.  The 
responsive mutation R344H was found in 4 families from Eastern and Northern 
Europe (2 from Poland, one from Czech Republic and one from Finland) and the 
responsive mutation S541L was reported in 4 families from France, Ireland, 
Poland and Portugal.  In general, the vast majority of patients is affected with at 
least one missense mutation interfering with the proper folding of the enzyme that 
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could be partially rescued by the treatment of the cells with the competitive 
inhibitor of HGSNAT, glucosamine.  We believe this makes MPS IIIC a good 
candidate for enzyme enhancement therapy [reviewed in 20,21] where active site-
specific inhibitors are used as pharmacological chaperones to modify the 
conformation of the mutant lysosomal enzymes usually retained and degraded in 
the ER in order to increase the level of the residual activity to a point sufficient to 
reverse the clinical phenotype.  Together with inhibitors of heparan sulfate 
synthesis, pharmacological chaperones could potentially reduce storage of this 
polymer in the central nervous system to levels sufficient to stop neuronal death 
and reverse inflammation.  
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MATERIALS AND METHODS 
The current study was conducted with ethics approval from the review board of 
CHU Ste-Justine, University of Montreal.  
Generation of expression constructs and site-directed mutagenesis 
The wild-type HGSNAT-TAP plasmid was obtained by subcloning the 
HGSNAT 1992 bp coding sequence into pCTAP vector (Stratagene).  Briefly, a 
3’ part of human pCMV-Script construct [11] missing the stop codon was 
amplified by PCR using primers 76-Cla-F 5’-TTG CTC TTA TAC TCA TGG 
TCT TTG TCA-3’ and TM76-R4 5’-ATA TGT CGA CGA GCC ATC CGA TTT 
TCC-3’ and then used to replace Cla I - Sal I segment of the same construct prior 
to subcloning into pCTAP using Hind III – Sal I sites. Missense mutants were 
constructed using QuikChange Lightning kit (Stratagene) with HGSNAT-TAP as 
a matrix (see Supplementary Table 1 for primers, Appendix IV). All primers were 
designed using QuikChange Primer Design Program 
(http://www.stratagene.com/qcprimerdesign). For all constructs the coding 
sequence included an extra 84 base pairs on their 5’ end (encoding 28 amino 
acids) as the sequence first described for HGSNAT gene [11], but for clarity the 
nomenclature used reflects a unified numbering system based on the sequence of 
GenBank entries NM_152419.2 and NG_009552.1 as in Fan et al. [12], Ruijter et 
al. [19], Fedele et al. [22] and Feldhammer et al. [13].  
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Cell culture and transfection 
Skin fibroblast lines of MPS IIIC patients, obtained with a written 
informed consent [11], and COS-7 cells (ATCC) were cultured in Eagles’s 
minimal essential medium supplemented with 10% (v/v) fetal calf serum 
(Wisent). Transfections were carried out using polyethyleneimine 25,000 (PEI, 
Polysciences inc.) or Lipofectamine LTX (Invitrogen).  PEI was dissolved in 
water at 1 mg/ml and pH was adjusted to 6.8 with HCl. For transfection, a 
mixture of 2 µg DNA and 8 µg PEI in 0.4 ml of serum free medium was 
incubated for 15 min at room temperature and added to ~70% confluent cells 
growing in a 10 cm dish.  The transfection media was replaced with growth 
media 18 h later.  Lipofectamine LTX was used as described in the 
manufacturer’s protocol. Patients (N273K and c.1726+1G>A) and control 
fibroblasts immortalized by transfection with retroviral vectors expressing the 
type 16 human papilloma virus E7 gene and the catalytic component of human 
telomerase were described before [25].  
 
Glucosamine-mediated refolding 
Patient and control skin fibroblasts were cultured as described above in 
growth media supplemented with various concentrations of D-(+)-glucosamine 
hydrochloride (Sigma G4875). Medium was replaced every day and at specified 
time cells were harvested and assayed for N-acetyltransferase activity and β-
hexosaminidase activity as described below.  
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Enzyme assays 
N-acetyltransferase enzymatic activity was measured using fluorogenic 
substrate, 4-methylumbelliferyl β-D-glucosaminide (4MU-βGlcN, Moscerdam, 
Rotterdam, The Netherlands) as previously described by He et al. [23].  The 
reaction mixture containing 5 μl of cell homogenate, 5 μl of 6 mM acetyl-CoA 
and 5 μl of 3 mM 4MU-βGlcN in McIlvain buffer (100 mM sodium citrate, 200 
mM sodium phosphate, pH 5.7) was incubated at 37ºC for 3-18 h. The reaction 
was terminated by adding 1.98 ml of 0.5 M Na2CO3/NaHCO3, pH 10.7, and 
fluorescence was measured and used to calculate the specific activity. Lysosomal 
β-hexosaminidase activity was measured as previously described [17].  Protein 
concentration was measured according to the method of Bradford [24] using a 
commercially available reagent (BioRad).  
 
Deglycosylation of HGSNAT.   
To remove N-linked glycans from HGSNAT cell homogenates were 
treated with recombinant endoglycosidase H, or peptide: N-Glycosidase F (Endo 
H; PNGase F  New England Biolabs). Briefly, the mix consisted of 10 µg of cell 
homogenate in 25 mM sodium phosphate buffer, pH 7.5, to which 1 µl (500 U) of 
concentrated Endo H or PNGase F was added before incubating at 37ºC overnight 
and analysis by Western blot.   
To inhibit glycosylation of newly-synthesized HGSNAT COS-7 cells 
transfected with plasmids coding for the wild-type enzyme and the C76F or 
P237Q variants were treated with 1 μg/ml of tunicamycin (Sigma) added 5 h after 
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transfection and allowed to express the recombinant protein for 48 h in the 
presence of drug.  Media and drug were changed after 24 h and the homogenates 
were analyzed by Western blot as described below. 
 
Western blotting 
Cell homogenates were sonicated and boiled in LDS sample buffer 
(Invitrogen) in the presence of 25 mM DTT. Proteins were resolved by SDS-
polyacrylamide gel electrophoresis using NuPAGE 4-12% Bis-Tris gels 
(Invitrogen) and electrotransferred to PVDF membrane. Detection of TAP-tagged 
N-acetyltransferase protein was performed using anti-calmodulin binding peptide 
epitope tag (CBP) rabbit antibodies (Immunology Consultants Laboratory, 
dilution 1:30,000) and the Amersham ECL Western Blotting Detection Reagents 
(GE Healthcare) in accordance with the manufacturer's protocol. 
 
Analysis of the wild-type recombinant HGSNAT by the anion-exchange 
FPLC.   
 COS-7 cells were harvested 42 h after transfection with the wild-type 
HGSNAT plasmid and suspended in lysis buffer (10 mM Tris-HCl, pH 7.5, 0.1% 
NP-40, 1 mM PMSF and Sigma P8340 protease inhibitor cocktail at 10 µl per 1 
ml of cell suspension). The homogenate was sonicated, gently shaked at 4 ºC for 
2 h and centrifuged at 13,000 rpm for 30 min. One ml of the supernatant 
containing 8 mg of total protein was applied to an ion-exhange Mono Q HR 5/5 
column equilibrated with 10 mM Tris buffer, pH 8.2. The column was washed 
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with 4 ml of the same buffer and then eluted using a 20 mL gradient of NaCl (0-
0.5 M) at a flow rate of 0.5 ml/min. One ml fractions were collected and assayed 
for N-acetyltransferase activity. Thirty μl aliquots from each fraction were 
analyzed by SDS-PAGE and Western blot using anti-calmodulin binding peptide 
epitope tag rabbit antibodies as described above.  
 
Confocal immunofluorescence microscopy 
Immortalized control human skin fibroblasts were transfected with 
HGSNAT-TAP or plasmids coding for the HGSNAT mutants using 
Lipofectamine LTX (Invitrogen) as described in the manufacturer’s protocol. 
Forty two hours post-transfection cells were incubated for 1 hour with 1 μM 
Lysotracker Red DND-99 (Invitrogen) and then washed with ice-cold PBS. Cells 
were fixed with 4% paraformaldehyde, 4% sucrose in PBS for 5 min, and then 
rinsed 3 times with PBS. Cells were permeabilized by 0.25% Triton X-100 for 10 
min and blocked for 1 h in 3% horse serum and 0.1% Triton X-100. Cells were 
either co-stained with rabbit anti-CBP (Immunology Consultants Laboratory; 
1:400) and mouse monoclonal anti-calnexin (Millipore; 1:250) antibodies in 3% 
horse serum, with anti-CBP antibodies and mouse monoclonal antibodies against 
human LAMP-2 (Developmental Studies Hybridoma Bank; 1:150), or with anti-
CBP antibodies and Lysotracker Red DND-99.  Cells were then counterstained 
with Oregon Green 488-conjugated anti-rabbit IgG antibodies or Texas-Red-
conjugated goat anti-mouse antibodies (Molecular Probes; 1:1000). Slides were 
studied on a Zeiss LSM510 inverted confocal microscope (Zeiss).  Images were 
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processed using the LSM image browser software (Zeiss) and Photoshop 
(Adobe). 
Accession numbers 
GenBank entries NM_152419.2 and NG_009552.1 
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FIGURE LEGENDS 
Figure 1. Enzymatic activity and expression of HGSNAT mutants.  
COS-7 cells were harvested 42 h after transfection with HGSNAT-TAP plasmids 
bearing missense mutations. Cell homogenates were (A) assayed for N-
acetyltransferase activity and (B) analyzed by Western blot using anti-CBP 
antibody as described in Materials and Methods.   
A. N-acetyltransferase activity is shown as a fraction of the activity measured in 
the cells transfected with the wild-type HGSNAT-TAP plasmid.  Values 
represent means ± S.D. of three independent experiments. 
B. Blot shows a representative image of triplicate experiments.  
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Figure 2. Deglycosylation of HGSNAT by endoglycosidase H, PNGase F and 
tunicamycin. 
COS-7 cells expressing either the wild-type HGSNAT or the protein containing 
C76F, P237Q, G262R or V481L variants were harvested 42 h post-transfection 
and their homogenates were treated overnight with endoglycosidase H (A) or 
PNGase F (B). (C) COS-7 cells expressing wild-type HGSNAT and C76F or 
P237Q variants were cultured for 48 h in the presence or absence of 1 μg/ml of 
tunicamycin added to the culture medium 5 h after the transfection.  The treated 
and control homogenates were analyzed by Western blot using anti-CBP 
antibodies as described in Materials and Methods. 
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Figure 3. Analysis of the wild-type recombinant HGSNAT by the anion-
exchange FPLC.   
COS-7 cells were harvested 42 h after transfection with the wild-type HGSNAT 
plasmid, solubilized in a buffer containing  0.1% NP-40, applied to an ion-
exhange Mono Q HR 5/5 column and eluted by 0-0.5 M NaCl gradient as 
described in Materials and Methods. Graph shows N-acetyltransferase activity 
(nmol/hr ml) in the collected fractions. Dashed line represents the NaCl gradient. 
An aliquot from each fraction was analyzed by Western blot using anti-CBP 
antibodies (inset).  
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Figure 4.  Localization of HGSNAT mutants expressed in cultured human 
skin fibroblasts by immunofluorescence microscopy. 
The cells transfected with wild-type or mutant HGSNAT-TAP constructs as 
indicated were fixed and stained with either mouse monoclonal anti-LAMP-2 
antibodies, Lysotracker Red DND-99 or mouse monoclonal anti-calnexin 
antibodies (red) and rabbit polyclonal anti-CBP antibodies (green) as indicated.  
Slides were studied on a Zeiss LSM510 inverted confocal microscope. 
Magnification 630x. Panels show representative images illustrating co-
localization of anti-CBP antibodies (green) and lysosomal and ER markers (red) 
for the wild-type HGSNAT, active enzyme containing P237Q polymorphism and 
inactive L137P and P571L mutants.  From 10 to 15 cells all showing similar 
localization patterns were studied for each variant.  See Supplementary figure 2 
for the data on other mutants, Appendix II.  
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Figure 5. Partial refolding of HGSNAT mutants by glucosamine. 
A. Fifty percent confluent immortalized skin fibroblasts from a MPS IIIC patient 
homozygous for N273K mutation [25] were cultured in the presence or absence 
of 14 mM D-(+)-glucosamine hydrochloride. Medium was replaced every day 
and at the indicated time intervals cells were harvested and assayed for the N-
acetyltransferase activity.  N-acetyltransferase activity is shown as a fraction of 
that measured in non-treated cells after 24 h of culturing. Data show mean values 
and standard error of 2 independent experiments. ** Significantly different 
(p<0.01) from non-treated cells according to repeated measurements ANOVA. 
B.  Same cells were cultured in the presence of increasing glucosamine 
concentrations (0-14 mM) for 5 days, harvested and assayed for N-
acetyltransferase activity or β-hexosaminidase activity.  Data show mean values 
and standard error of 2 independent experiments. 
C.  Primary skin fibroblasts of the MPS IIIC patients carrying the missense 
HGSNAT mutations: L137P/S518F (P1), P283L/R344C (P3), S518F/S518F 
(P4), N273K/N273K (P6), R344C/R344C (P7), S518F/S518F (P8) and 
E471K/D562V (P9) or a missense mutation in combination with a splice site 
(S541L/c.234+1G>A; P2) or nonsense (R344H/R384X, P5) mutation were 
cultured for 2 (P1, P2, P5, P6, P8, P9) or 3 (P3, P4, P7) days in the absence (open 
bars) or presence (filled bars) of 7 mM (P3-P9) or 14 mM (P1, P2) glucosamine, 
harvested and assayed for N-acetyltransferase activity.  Data show mean values 
and standard error of 2 independent experiments.  The residual N-
acetyltransferase activity detectable in untreated cells most likely represents 
background chemical or enzymatic reactions occurring with the substrate in the 
presence of cell homogenates. 
Significantly (*, p<0.05; **, p<0.01; ***, p<0.001) different from non-treated 
cells according to non-parametric t-test. 
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Figure 6. Distribution of missense mutations in HGSNAT protein.   
Visual representation of HGSNAT membrane topology was created using the 
TMRPres2D software [26].  The deduced amino acid sequence of HGSNAT 
predicts 11 transmembrane domains and five potential N-glycosylation sites 
oriented towards the lysosomal lumen (shown in blue).  Mutations that result in 
production of misfolded proteins are shown in red.  Polymorphisms are shown in 
green. Figure was adapted from our previous work [13]. 
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General Discussion 
Our studies represent the first major characterization of the molecular 
defects of HGSNAT in MPS IIIC as well as the first comprehensive review of 
patient mutations. We have identified 10 novel mutations present in diverse 
patient populations and speculated on their contributions to pathogenesis. We 
further showed enzyme misfolding to be the underlying molecular defect in 
patients with missense mutations explaining their severe disease progression. 
Additionally we identified and utilized the pharmalogical chaperone glucosamine 
to rescue mutant enzyme activity in these patient fibroblasts. 
To date 54 HGSNAT mutations have been reported in the literature 
including 13 splice-site mutations, 11 insertions and deletions, 8 nonsense, 18 
missense and 4 polymorphisms. The mutations are found throughout the 18 exons 
and affect 8 of the 11 transmembrane domains of the protein as well as its 
cytosolic and luminal domain. Interestingly, a majority of the missense mutations 
are located within the predicted transmembrane domains or on adjacent residues 
within the lumen. These mutations are likely to affect the native folding of the 
enzyme by destabilizing the transmembrane helix as well as potentially 
interfering with sites important for binding of AcCoA, its transport through 
lysosomal membrane or areas important for the catalytic activity of the enzyme.  
Despite the relative heterogeneity seen in patient mutations, there are 
several mutations with higher frequencies suggesting possible founder effects. 
Two of the more frequent mutations p.R344C and p.S518F are found primarily in 
Dutch patients. These mutations account for 22% and 29.3% of the probands of 
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Dutch origin respectively, representing potential founder mutations [81]. Founder 
mutations are generally frequent among Dutch patients due to a high genetic 
homogeneity among this population [83]. The p.S518F mutation was found 
exclusively in Dutch patients and one patient from Germany. Interestingly, 3 of 
11 Italian patients were homozygous for the mutation c.852-1G>A, all of whom 
had origins in the south of Italy [80]. Another frequent mutation was c.525dupT 
reported in 5 of 6 alleles of Portuguese patients, suggesting a potential founder 
mutation in the Portuguese population. We further reported two different 
Portuguese patients each homozygous for the c.525dupT mutation supporting the 
idea of a founder mutation in the Portuguese patient population  
Other reported mutations: splicing mutations, insertions, deletions and 
nonsense mutations will all predictably result in mRNA which is either 
improperly spliced, or contains a PTC resulting in rapid degradation of the 
transcript and therefore complete absence of the HGSNAT enzyme.  
As mentioned, a majority of MPS IIIC patients experience a severe 
clinical progression due to an almost complete absence of HGSNAT activity. 
Exceptionally, the 2 mutations p.G262R and p.S539C likely cause a late onset 
form of MPSIII as a combination of these mutations was only found in two sisters 
with the attenuated form of the disease. 
In order to understand the reason behind the severe disease progression 
seen in patients with missense mutations; we have conducted the initial 
biochemical characterization of the HGSNAT enzyme, as well as mutational 
analysis of all known missense mutations. We studied the activity and biogenesis 
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of all 21 previously reported missense mutations by expressing recombinant 
forms in various cell types.  
We determined that HGSNAT missense mutants with the exception of the 4 
polymorphisms are inactive, misfolded and retained in the ER where they are 
abnormally glycosylated. As mentioned, many of the missense mutations affected 
residues within or adjacent to the transmembrane domains of the enzyme, 
therefore the introduction of amino acids with different charge, size or 
hydrophobicity can destabilize the helix and have drastic effects on protein 
folding.  
Once we determined MPS IIIC to be a folding disorder we screened 
potential chaperone molecules for their ability to stabilize the active conformation 
of HGSNAT. We identified glucosamine as an active site-specific chaperone 
(ASSC) of HGSNAT and showed that it could rescue the active conformation in 
8 of 9 patient cell lines tested. We therefore believe chaperone therapy to be a 
good treatment option for MPS IIIC as a majority of patients are affected with at 
least one missense mutation interfering with proper enzyme folding which could 
be partially rescued by the ASSC glucosamine. 
Many questions about the biochemistry of HGSNAT remain unanswered. 
It is still not clear exactly how the enzyme exerts its N-acetyltransferase function, 
what residues are important for its catalytic activity and where the substrates 
glucosamine and AcCoA bind. We also do not know for sure in what oligomeric 
form the enzyme is present in vivo, or even how HGSNAT is targeted to the 
lysosome. Answers to these questions will provide a better understanding of the 
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disease mechanism and will allow for the development of better therapies to help 
patients suffering from this and similar disorders. 
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Conclusions 
 
1. We have identified 10 novel mutations in HGSNAT including 3 splicing 
mutations, 2 deletions, 1 insertion, 2 nonsense mutations and 2 missense 
mutations identified in 14 MPS IIIC patients. Molecular and clinical information 
on these as well as on all previously reported mutations was summarized in a 
comprehensive review. 
 
2. We determined that 4 previously reported amino acid changes in HGSNAT 
were in fact polymorphisms which had no effect on enzyme activity, targeting or 
glycosylation and therefore were not clinically significant. 
 
3. We expressed in COS 7 cells and human fibroblasts HGSNAT mutants 
containing all 17 reported amino acid changes and showed that they all lacked 
enzymatic activity, proper glycosylation and proteolytic cleavage occurring with 
the wild type enzyme in the lysosome.  
 
4. We further showed that HGSNAT missense mutants in contrast to wild type 
enzyme and enzyme containing polymorphisms were not properly trafficked to 
the lysosome, but were retained in the ER.  
 
5. We showed that a competitive inhibitor of HGSNAT, glucosamine can act as a 
molecular chaperone, rescuing HGSNAT activity in 8 of 9 patient fibroblast lines 
tested. 
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Figure S1. Lineweaver-Burk plot of substrate dependance for partially purified 
HGSNAT wild-type and P237Q and V481L mutants. COS-7 cells were harvested 
42 hrs after transfection with the wild-type or mutant HGSNAT plasmids and 
suspended in lysis buffer (40 mM Tris-HCl, 300 mM KCl, pH 7.5, 0.1% NP-40, 1 
mM PMSF and Sigma P8340 protease inhibitor cocktail at 10 µl per 1 ml of cell 
suspension). The homogenate was sonicated, gently shaked at 4°C for 2 h and 
centrifuged at 13,000 rpm for 30 min. The supernatant was first passed through 
an avidin-agarose column (Sigma A9207) then affinity purification of TAP-
tagged HGSNAT was performed using streptavidin resin (Stratagene) according 
to the manufacturer's protocol. N-acetyltransferase activity was assayed as 
described in Material and Methods using 0.05 to 2.0 mM 4MU-βGlcN and 18 h 
incubation time. KM and VMAX values for all 3 enzymes were similar within the 
statistical error. 
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Figure S2.  Localization of HGSNAT mutants expressed in cultured human skin 
fibroblasts by immunofluorescence microscopy. The cells transfected with wild-
type or mutant HGSNAT-TAP constructs as indicated were fixed and stained 
with either mouse monoclonal anti-LAMP-2 antibodies, Lysotracker Red DND-
99 or mouse monoclonal anti-calnexin antibodies (red) and rabbit polyclonal anti-
CBP antibodies (green) as indicated. Slides were studied on a Zeiss LSM510 
inverted confocal microscope. Magnification 630x. Panels show representative 
images showing co-localization of anti-CBP antibodies (green) and lysosomal 
and ER markers (red) for the active enzyme containing polymorphisms and all 
inactive mutants. 
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Figure S3.  Dixon plot showing the inhibition of HGSNAT by glucosamine. 
COS-7 cells were harvested 42 hrs after transfection with the wild-type HGSNAT 
plasmid and N-acetyltransferase activity was measured in the homogenates for 3 
h at 37°C in the presence of 2 mM AcCoA, 0.0375 to 1.5 mM 4MU-βGlcN and 0 
to 2 mM D-(+)-glucosamine hydrochloride. 
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APPENDIX IV 
 xxv
Mutant Sense Primer Antisense Primer 
C76F ctactggaaatctgaatgcttttatcactgcttgtttcagg cctgaaacaagcagtgataaaagcattcagatttccagtag 
L137P tggagaatttggaaactattctcccttggtaaagaacatccataat attatggatgttctttaccaagggagaatagtttccaaattctcca 
P237Q atctgccctgcagccccgcctcc ggaggcggggctgcagggcagat 
G262R tggtctttgtcaattatggaggaagaaaatattggtacttcaaacat atgtttgaagtaccaatattttcttcctccataattgacaaagacca 
N273K tacttcaaacatgcaagttggaaggggctgacagtg cactgtcagccccttccaacttgcatgtttgaagta 
P283L tggctgacctcgtgttcctgtggtttgtatttattatg cataataaatacaaaccacaggaacacgaggtcagcca 
R344C tcttgggacaaggtgtgcattcctggtgtgc gcacaccaggaatgcacaccttgtcccaaga 
R344H cttgggacaaggtgcacattcctggtgtgct agcacaccaggaatgtgcaccttgtcccaag 
W403C gctggaaggcctgtgtctgggcttgacattc gaatgtcaagcccagacacaggccttccagc 
G424S gttatcttggtcctgggagcattggagattttggc gccaaaatctccaatgctcccaggaccaagataac 
E471K ggcctatgaccccaagggcatcctggg ccggatactggggttcccgtaggaccc 
V481L gcaccatcaactccatcttgatggcctttttagga tcctaaaaaggccatcaagatggagttgatggtgc 
M482K gcaccatcaactccatcgtgaaggcctttttagg cctaaaaaggccttcacgatggagttgatggtgc 
A489E atggcctttttaggagttcaggaaggaaaaatactattgtattaca tgtaatacaatagtatttttccttcctgaactcctaaaaaggccat 
S518F ttgtattcttgggctcatttttgttgctctgacgaagg ccttcgtcagagcaacaaaaatgagcccaagaatacaa 
K523Q catttctgttgctctgacgcaggtttctgaaaatgaagg ccttcattttcagaaacctgcgtcagagcaacagaaatg 
S539C ccagtaaacaaaaatctctggtgcctttcgtatgtcactac gtagtgacatacgaaaggcaccagagatttttgtttactgg 
S541L aaaatctctggtcccttttgtatgtcactacgctcag ctgagcgtagtgacatacaaaagggaccagagatttt 
D562V tgtacccagttgtggttgtgaaggggctgtg cacagccccttcacaaccacaactgggtaca 
P571L gctgtggacaggaaccctattcttttatccaggaa ttcctggataaaagaatagggttcctgtccacagc 
A615T ctcagaacatcgtcaccactgccctctgg ccagagggcagtggtgacgatgttctgag 
 
Table S1. Primers for site-directed mutagenesis of HGSNAT-TAP plasmid. 
 
  
 
 
 
 
 
 
 
 
 
